,ProtocolNum,ProductName,FullTitle,ProtocolPhase,ProtocolStatus,TA,PlannedEnrollment,ActualEnrollment,ActualScreened,ActualRescreened,ActualScreenFailure,ActualRandomizedDosed,ActualEarlyTerminated,PercEnrollmentCompleted,PlannedSites,ActiveSites,LegacyCompany,CRO,PlannedPrimaryStudy_CompletionDate,ActualPrimaryStudy_CompletionDate,SynopsisActualDate,Protocol_ActualDate,FirstSiteActivated_ActualDate,FSS_ActualDate,FSI_ActualDate,FSFV_ActualDate,LSI_ActualDate,LSI_AvgTx_ActualDate,LSO_ActualDate,LSO_2_ActualDate,LSO_3_ActualDate,LSO_4_ActualDate,LSO_Final_ActualDate,DBL_ActualDate,DBL_2_ActualDate,DBL_3_ActualDate,DBL_4_ActualDate,DBL_Final_ActualDate,CloseOut,numValsLSO,numValsDBL,PrimaryStudy_to_Synopsis,Synopsis_to_Protocol,Protocol_to_FirstSiteActivated,FirstSiteActivated_to_FSS,FSS_to_FSI,FSI_to_FSFV,FSFV_to_LSI,LSI_to_LSIAvgTxL,LSI_to_LSO
0,TAK-071-1002,TAK-071,"A Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, 5-Period Crossover Phase 1b Study To Evaluate The Effects Of Single Oral Administration of TAK-071 On Scopolamine-Induced Cognitive Impairment In Healthy Subjects",I,Terminated,NS,46,18,183,0,165,0,12,39.13%,1,1,0,PPD,0,,2016-05-31,2016-08-08,,2016-11-21,2016-12-05,,2017-06-19,,2017-08-08,,,,,2018-05-24,,,,,289,5,5,,69,,,14,,,,50
7,C16014  Korea Continuation,Ninlaro,"South Korea Continuation Study - A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma",III,Recruitment Complete,Oncology,40,41,60,0,19,0,8,102.50%,11,0,0,PPD,0,,,2015-09-09,,,2016-06-01,,2017-04-05,2019-07-30,2019-12-02,,,,,2020-01-22,,,,,51,5,5,,,,,,,,846,971
9,C34007,TAK-659,C34007 Phase 1 Asian Lymphoma single agent  (40 pts),I,Recruitment Complete,Oncology,22,17,0,0,6,11,0,77.27%,5,0,0,IQVIA,0,,2016-09-22,2017-03-21,,,2017-09-07,,2019-09-25,2020-08-17,2020-08-17,,,,,2020-10-15,,,,,59,5,5,,180,,,,,,327,327
11,TAK-438_115,vonoprazan,"A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With TAK-438 Versus Quadruple Therapy With Lansoprazole.",I,Closed,GI,30,30,211,0,181,0,0,100.00%,1,0,0,IQVIA,0,,2013-01-25,2015-12-22,,2016-09-05,2016-09-21,,2017-03-30,,2017-05-11,,,,,2017-05-17,,,,,6,5,5,,1061,,,16,,,,42
14,TAK-438_302,vonoprazan,"A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter pylori Infection",III,Terminated,GI,830,236,5,0,114,1,0,28.43%,68,0,0,IQVIA,0,,2012-12-06,2014-05-07,,2017-04-17,2017-06-15,,2020-01-22,,2020-03-17,,,,,2020-07-07,,,,,112,5,5,,517,,,59,,,,55
15,TAK-438_304,vonoprazan,"A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Duodenal Ulcer Subjects With or Without Helicobacter pylori Infection",III,All Activities Closed,GI,530,530,3,0,248,1,0,100.00%,68,0,0,IQVIA,0,,2012-12-06,2012-11-21,,2017-04-05,2017-05-04,,2019-01-29,,2019-04-12,,,,,2019-09-05,,,,,146,5,5,,-15,,,29,,,,73
16,TAK-935-1005,soticlestat (TAK-935),A Phase 1 Bioavailability and Food Effect Study to Compare Tablet versus Solution Formulation and to Assess the Effect of  Food on the Bioavailability of a Single TAK-935 Dose in Healthy Subjects,I,Closed,NS,9,9,21,0,12,0,0,100.00%,1,1,0,PPD,0,,2016-04-29,2016-06-28,,2016-09-06,2016-10-04,,2016-10-04,,2016-11-09,,,,,2017-01-11,,,,,63,5,5,,60,,,28,,,,36
17,TAK-418-1001,TAK-418,"A Randomized, Double-Blind, Placebo-Controlled, Ascending Oral Single Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-418 in Healthy Subjects",I,Closed,NS,40,40,146,0,106,40,2,100.00%,1,1,0,PRA,0,,2016-08-03,2017-04-07,,2017-06-27,2017-08-08,,2017-11-14,,2018-05-12,,,,,2018-06-07,,,,,26,5,5,,247,,,42,,,,179
20,TAK-418-0004,TAK-418,"A Study Measuring LSD-1 Occupancy in Healthy Adult Volunteers as a Function of TAK-418 Dose, TAK-418 Plasma Concentration and Liquid Biomarker [18F]MNI-1054",I,Terminated,NS,16,7,10,0,3,6,1,43.75%,1,0,0,PRA,0,,2019-07-04,2019-12-19,,2020-03-05,2020-01-08,,2020-03-03,,2020-03-19,,,,,2020-07-29,,,,,132,5,5,,168,,,-57,,,,16
28,Lubiprostone-3001,Amitiza (lubiprostone),"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation",III,Closed,NonCore,204,173,0,0,13,0,0,84.80%,20,0,0,IQVIA,0,,,2015-05-13,,2016-02-17,2016-03-02,,2016-12-06,,2017-01-23,,,,,2017-03-21,,,,,57,5,5,,,,,14,,,,48
29,Lubiprostone-3002,Amitiza (lubiprostone),"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation",III,Closed,NonCore,150,108,0,0,17,21,0,72.00%,13,0,0,IQVIA,0,,,2015-05-14,,2016-04-14,2016-05-06,,2017-01-06,,2017-02-17,,,,,2017-04-21,,,,,63,5,5,,,,,22,,,,42
30,Lubiprostone-3003,Amitiza (lubiprostone),"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic, Idiopathic Constipation",III,Closed,NonCore,204,172,0,0,50,0,0,84.31%,12,0,0,IQVIA,0,,,2015-05-20,,2016-05-11,2016-05-25,,2017-04-28,,2017-06-05,,,,,2017-07-28,,,,,53,5,5,,,,,14,,,,38
43,TAK-041-1002,TAK-041,"A Phase, Open-Label, Randomized, Positron Emission Tomography Study in Healthy Subjects to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the CNS After Single-Dose Oral Administration",I,Closed,NS,12,12,33,0,21,0,2,100.00%,1,1,0,IQVIA,0,,2016-06-01,2016-07-20,,2016-12-26,2017-01-18,,2017-05-29,,2017-08-24,,,,,2017-10-19,,,,,56,5,5,,49,,,23,,,,87
52,TAK-390MR_106,"DEXILANT (dexlansoprazole, MR)","A Phase 1, Single-Center, Open-Label, 2-Arm Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 mg and 60 mg Capsules in Healthy Chinese Subjects",I,Closed,GI,40,40,226,0,186,0,0,100.00%,1,0,0,Hangzhou Tigermed Consulting,0,,2011-08-05,2014-11-28,,2017-11-22,2017-12-07,,2018-01-25,,2018-02-08,,,,,2018-03-23,,,,,43,5,5,,1211,,,15,,,,14
53,TAK-390MR_301,"DEXILANT (dexlansoprazole, MR)","A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and Maintenance of Healing in Subjects With Healed Erosive Esophagitis With Dexlansoprazole (30 mg QD) and Placebo",III,Terminated,GI,450,37,66,0,28,0,34,8.22%,25,0,0,Hangzhou Tigermed Consulting,0,,2011-08-05,2014-11-28,,2016-12-09,2016-12-30,,2017-08-23,,2017-10-30,,,,,2017-11-30,,,,,31,5,5,,1211,,,21,,,,68
54,TAK-390MR_302,"DEXILANT (dexlansoprazole, MR)",A Phase 3 Double Blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) compared to Placebo on Heartburn Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD),III,Closed,GI,200,217,326,0,108,0,12,108.50%,20,0,0,Hangzhou Tigermed Consulting,0,,2011-08-05,2014-11-28,,2016-12-09,2016-12-31,,2018-02-12,,2018-04-10,,,,,2018-05-11,,,,,31,5,5,,1211,,,22,,,,57
61,Alogliptin-1002,OSENI (alogliptin and pioglitazone),"A Randomized, Open-Label, Single-Dose, 4-Period Crossover Study to Determine the Bioequivalence of Alogliptin (25 mg) and Pioglitazone (15 and 30 mg) When Administered as Individual Tablets and as Fixed-Dose Combination Tablets to Healthy Russian Subjects",I,Closed,NonCore,72,72,112,0,40,0,4,100.00%,1,0,0,Atlant,0,,2017-01-30,2017-07-26,,2018-05-24,2018-06-01,,2018-06-08,,2018-07-13,,,,,2018-09-12,,,,,61,5,5,,177,,,8,,,,35
69,VedolizumabSC-1017,Entyvio SC,"A Phase 1, Open-Label, Randomized, Parallel Group Pilot Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Needle Safety Device in Healthy Subjects",I,Closed,GI,24,24,47,0,23,0,0,100.00%,1,0,0,Celerion,0,,,2017-12-17,,2018-02-06,2018-02-26,,2018-02-26,,2018-08-12,,,,,2018-09-19,,,,,38,5,5,,,,,20,,,,167
74,Esomeprazole-1001,vonoprazan,"A Phase 1, Randomized, Open-label, 2-way Cross-over Study to Evaluate the Bioequivalence Between a Single Oral Dose of Esomeprazole 40 mg Capsules and Esomeprazole 40 mg Tablets in Healthy Subjects",I,Closed,GI,52,52,110,0,58,0,2,100.00%,1,0,0,PRA,0,,2016-09-23,2017-01-31,,2017-03-27,2017-04-22,,2017-05-05,,2017-05-13,,,,,2017-06-26,,,,,44,5,5,,130,,,26,,,,8
77,Vedolizumab-2004,Entyvio,"An open-label, dose-finding study of intravenous (IV) vedolizumab for treatment of steroid-refractory graft-versus-host disease (GvHD) in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT)",II,Closed,GI,17,17,0,0,3,16,0,100.00%,15,0,0,IQVIA,0,,2016-05-17,2016-08-26,,2017-04-28,2017-04-28,,,,2018-05-09,,,,,2018-10-10,,,,,154,5,5,,101,,,0,,,,
82,C16029,Ninlaro,"A Phase 2/3, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma",III,Recruitment Complete,Oncology,120,122,195,0,73,122,0,101.67%,117,30,0,PPD,0,,,2017-03-29,,,2018-02-22,,2019-10-07,,2020-03-26,,,,,2020-09-04,,,,,162,5,5,,,,,,,,,171
108,TBD-1-1MYTTL,TAK-671,TAK-671-SRD,I,Planned,GI,48,0,0,0,0,0,0,0,1,0,0,TBD,0,,2017-11-23,2018-03-29,,2018-08-30,2018-09-18,,2020-02-05,,2020-04-16,,,,,2020-06-16,,,,,61,5,5,,126,,,19,,,,71
111,TAK-935-2001,soticlestat (TAK-935),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study With an Open-Label Phase to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects With Developmental and/or Epileptic Encephalopathies",II,Closed,NS,18,18,26,0,8,0,4,100.00%,10,0,0,PRA,0,,2016-10-17,2017-04-05,,2017-06-13,2017-08-17,,2018-06-14,,2018-10-12,,,,,2018-11-02,,,,,21,5,5,,170,,,65,,,,120
115,TBD-1-1P9TDT,soticlestat (TAK-935),"Assessment and validation of Plasma Biomarker, 24 Hydroxycholesterol (24 HC), in Epilepsy Syndromes in Children and Adults",0,Terminated,NS,100,0,0,0,0,0,0,0,3,0,0,TBD,0,,2019-01-22,2019-03-26,,2019-06-25,2019-06-25,,2019-12-17,,2019-12-25,,,,,2020-02-19,,,,,56,5,5,,63,,,0,,,,8
116,TAK-041-2001,TAK-041,"A randomized, double-blind, placebo-controlled, three-period cross-over study to evaluate the effects of add-on TAK-041 on motivation and reward in stable patients with Schizophrenia.",II,All Activities Closed,NS,23,24,86,0,62,86,4,104.35%,1,1,0,PRA,0,,2017-03-13,2017-04-26,,2018-03-09,2018-03-15,,2019-08-02,,2019-11-08,,,,,2019-12-12,,,,,34,5,5,,44,,,6,,,,98
120,Vedolizumab-1019,Entyvio,PK Study_2nd gen cell line (Vedolizumab),I,Completed,GI,190,190,375,0,0,0,0,100.00%,1,0,0,Celerion,0,,2019-04-17,2019-10-04,,2019-12-02,2019-12-05,,2020-02-18,,2020-07-06,,,,,2020-10-09,,,,,95,5,5,,170,,,3,,,,139
125,TAK-954-1005,TAK-954,NHV ADME Study,I,Closed,GI,6,6,11,0,1,6,1,100.00%,1,0,0,PRA,0,,2017-12-13,2018-03-15,,2018-04-27,2018-05-18,,2018-05-18,,2018-06-01,,,,,2018-11-08,,,,,160,5,5,,92,,,21,,,,14
126,TAK-954-1004,TAK-954,"A Fixed Sequence, Open-Label, 2-Period Crossover Trial to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics of TAK-954 in Healthy Adult Subjects",I,Closed,GI,11,10,27,0,8,0,0,90.91%,1,0,0,PRA,0,,2016-12-10,2017-05-03,,2017-06-27,2017-06-27,,2017-06-27,,2017-07-24,,,,,2017-08-28,,,,,35,5,5,,144,,,0,,,,27
129,TAK-954-1007,TAK-954,"An Open-Label, Parallel Group Study to Evaluate the Effect of Renal Impairment and dialysis treatment on the Pharmacokinetics (PK) of TAK-954 following a single intravenous dose of TAK-954.",I,All Activities Closed,GI,32,32,55,0,22,0,1,100.00%,4,4,0,PRA,0,,2017-06-01,2017-06-29,,2017-11-20,2017-12-01,,2019-07-30,,2019-08-12,,,,,2019-09-06,,,,,25,5,5,,28,,,11,,,,13
130,TAK-954-1006,TAK-954,"A Phase 1 Non-Randomized, Open-Label Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics of Intravenous TAK-954",I,Closed,GI,24,25,34,0,9,0,2,104.17%,2,2,0,PRA,0,,2017-04-17,2017-05-26,,2017-11-09,2017-12-12,,2018-08-28,,2018-09-10,,,,,2018-10-15,,,,,35,5,5,,39,,,33,,,,13
133,TAK-954-2002,TAK-954,"A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intolerance",II,Terminated,GI,200,1,3,0,2,0,1,0.50%,40,0,0,PRA,0,,2017-11-20,2018-01-19,,2018-08-25,2018-08-25,,2018-08-25,,2018-08-29,,,,,2019-02-01,,,,,156,5,5,,60,,,0,,,,4
140,TAK-831-2001,TAK-831,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects,  Safety, Tolerability and Pharmacokinetics of Multiple Doses of  Oral TAK-831 in Adult Patients with Schizophrenia",II,Completed,NS,40,31,52,0,21,31,6,77.50%,3,2,0,PRA,0,,2017-03-21,2017-05-03,,2018-01-04,2018-03-20,,2020-11-11,,2020-12-21,,,,,2021-02-15,,,,,56,5,5,,43,,,75,,,,40
143,Cx611-0204,Alofisel,SEPCELL,II,Completed,GI,80,84,90,0,6,0,0,105.00%,27,0,0,TFS,0,,2017-01-31,2017-01-31,,2017-01-31,2017-01-31,,2019-12-17,,2020-07-31,,,,,2020-10-15,,,,,76,5,5,,0,,,0,,,,227
146,TAK-906-1002,TAK-906,"A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled  Trial to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Subjects with Diabetes Mellitus with Gastroparesis (DG) or Idiopathic Gastroparesis (IG)",II,Closed,GI,48,51,76,0,25,0,3,106.25%,9,0,0,PRA,0,,2016-12-13,2017-05-24,,2017-09-25,2017-10-04,,2018-02-20,,2018-03-11,,,,,2018-07-19,,,,,130,5,5,,162,,,9,,,,19
157,TAK-925-1002,TAK-925,"A Phase 1b, 4-Period Crossover, Placebo-Controlled, Randomized, Single Dose Study to
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-925 in
Sleep-Deprived Healthy Adults Utilizing Modafinil as an Active Comparator",II,Closed,NS,20,20,77,0,57,20,2,100.00%,1,0,0,PRA,0,,2018-01-31,2018-03-08,,2018-05-04,2018-05-30,,2018-09-18,,2018-11-07,,,,,2018-12-11,,,,,34,5,5,,36,,,26,,,,50
158,Brigatinib-2002,Alunbrig,"Brigatinib in Patients with Anaplastic Lymphoma Kinase (ALK)-positive, Advanced Non-small Cell Lung Cancer (NSCLC) progressed with Alectinib or Ceritinib)",II,Recruitment Complete,Oncology,103,104,123,0,19,0,103,100.97%,89,61,0,TBD,0,,,2018-10-06,,,2019-02-12,,2019-12-30,,2020-09-30,,,,,2020-11-26,,,,,57,5,5,,,,,,,,,275
159,TAK-418-1003,TAK-418,"TAK-418 ,MRD",I,Closed,NS,48,24,0,0,0,0,0,50.00%,2,0,0,PRA,0,,2018-02-05,2018-03-23,,2018-05-28,2018-07-10,,,,2019-01-18,,,,,2019-02-12,,,,,25,5,5,,46,,,43,,,,
161,VedolizumabSC-1021,Entyvio SC,"A Phase 1, Open-Label, Randomized, Parallel Group Pilot Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Autoinjector in Healthy Subjects",I,Closed,GI,24,24,58,0,34,0,0,100.00%,2,0,0,Celerion,0,,,2017-12-18,,2018-02-22,2018-03-10,,2018-03-10,,2018-08-24,,,,,2018-10-05,,,,,42,5,5,,,,,16,,,,167
162,VedolizumabSC-1022,Entyvio SC,"A Phase 1, Open-Label, Randomized, Parallel Group Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Autoinjector in Healthy Subjects",I,Closed,GI,204,204,369,0,165,0,3,100.00%,2,0,0,Celerion,0,,,2017-12-18,,2018-03-12,2018-03-24,,2018-06-10,,2018-11-21,,,,,2018-12-11,,,,,20,5,5,,,,,12,,,,164
163,TAK-788-1001,Mobocertinib (TAK-788),Ph1 SRD NHV/Pilot Food Effect,I,All Activities Closed,Oncology,68,68,161,0,97,0,0,100.00%,1,0,0,PRA,0,,2017-12-05,2018-02-08,,2018-03-28,2018-04-18,,2018-12-12,2019-01-18,2019-01-18,,,,,2019-05-22,,,,,124,5,5,,65,,,21,,,37,37
193,TAK-935-2006,soticlestat (TAK-935),"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Pediatric Patients with Developmental and/or Epileptic Encephalopathies",II,Completed,NS,124,141,173,0,32,0,15,113.71%,45,0,0,PPD,0,,,2018-02-20,,2018-08-08,2018-09-19,,2020-01-23,,2020-06-09,,,,,2020-07-20,,,,,41,5,5,,,,,42,,,,138
197,TAK-951-1001,TAK-951,TAK-951 FIH,I,Completed,GI,128,124,124,0,0,0,0,96.88%,1,0,0,PRA,0,,2018-10-05,2019-01-04,,2019-02-26,2019-03-25,,2020-09-23,,2020-11-02,,,,,2021-02-26,,,,,116,5,5,,91,,,27,,,,40
210,TAK-418-0002,TAK-418,"An open-label, brain positron emission tomography, Phase 0 study of [18F]MNI-1054 as a marker for Lysine-specific histone demethylase 1A (LSD1) Human Validation Study",0,Closed,NS,12,0,0,0,0,0,0,0.00%,1,0,0,0,0,,2018-07-13,2018-07-16,,2018-08-27,2018-09-14,,2018-10-12,,2018-11-06,,,,,2018-11-07,,,,,1,5,5,,3,,,18,,,,25
215,TAK-935-2004,soticlestat (TAK-935),"A MULTICENTER, OPEN-LABEL, PILOT STUDY OF TAK-935 IN PATIENTS WITH 15Q DUPLICATION SYNDROME OR CDKL5 DEFICIENCY DISORDER",II,Completed,NS,30,20,28,0,8,0,2,66.67%,3,0,0,PPD,0,,2018-03-09,2018-05-22,,2018-09-10,2018-10-08,,2020-06-19,,2020-07-13,,,,,2020-07-31,,,,,18,5,5,,74,,,28,,,,24
218,TAK-925-2002,TAK-925,"A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia",II,Completed,NS,40,28,0,0,41,28,0,70.00%,10,0,0,IQVIA,0,,2019-06-13,2019-08-06,,2020-01-26,2020-03-10,,2020-11-17,,2020-11-25,,,,,2021-01-21,,,,,57,5,5,,54,,,44,,,,8
219,TAK-925-2001,TAK-925,"A Phase 1b Randomized, Double-blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of TAK-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of CPAP",II,All Activities Closed,NS,42,25,119,0,94,25,2,59.52%,18,0,0,IQVIA,0,,2019-07-15,2019-08-06,,2019-11-19,2019-12-01,,2020-03-22,,2020-04-02,,,,,2020-06-18,,,,,77,5,5,,22,,,12,,,,11
220,TAK-906-1009,TAK-906,"A OPEN-LABEL, 2-PERIOD, CROSSOVER STUDY TO EVALUATE THE EFFECT OF OATP1B1 AND OATP1B3 INHIBITOR ON THE PHARMACOKINETICS OF ORAL TAK-906 IN HEALTHY ADULT SUBJECTS",I,All Activities Closed,GI,12,12,34,0,0,0,0,100.00%,1,0,0,Celerion,0,,2019-07-10,2019-09-20,,2019-10-12,2019-10-25,,2019-10-25,,2019-11-12,,,,,2020-01-06,,,,,55,5,5,,72,,,13,,,,18
274,TAK-935-1008,soticlestat (TAK-935),ADME/ABA (TAK-935),I,Planned,NS,16,16,0,0,0,0,0,100.00%,1,0,0,Celerion,0,,2020-02-24,2020-06-08,,2020-07-07,2020-07-09,,2020-07-17,,2020-08-16,,,,,2020-09-18,,,,,33,5,5,,105,,,2,,,,30
308,TAK-994-1006,TAK-994,"A Phase 1, Relative Bio-Availability Study of TAK-994 in Normal Healthy Volunteers",I,Recruitment Complete,NS,54,54,119,0,0,0,0,100.00%,2,0,0,Celerion,0,,2020-10-15,2020-12-17,,2021-02-16,2021-03-02,,2021-03-12,,2021-04-05,,,,,2021-05-07,,,,,32,5,5,,63,,,14,,,,24
316,TAK-951-1004,TAK-951,A Ph1 IV PK profiling study in healthy volunteers,I,Completed,GI,40,32,112,0,0,0,0,80.00%,1,0,0,Celerion,0,,2020-02-14,2020-05-11,,2020-07-07,2020-10-09,,2021-04-18,,2021-05-16,,,,,2021-06-14,,,,,29,5,5,,87,,,94,,,,28
333,TAK-925-1013,TAK-925,PK study - TAK-925 and Cobicistat,I,All Activities Closed,NS,16,16,37,0,0,0,0,100.00%,1,0,0,Celerion,0,,2019-11-25,2020-01-24,,2020-02-11,2020-02-25,,2020-02-26,,2020-03-13,,,,,2020-04-24,,,,,42,5,5,,60,,,14,,,,16
358,TAK-935-1004,soticlestat (TAK-935),A phase 1 study to characterize the safety and tolerability profile of TAK-935 following single and multiple dose with titration in healthy Japanese adults subjects.,I,Reported,NS,32,0,0,0,0,0,0,0.00%,1,0,0,PRA,0,,2020-03-05,2020-05-11,,2020-08-13,2020-08-24,,2020-10-21,,2020-11-14,,,,,2021-03-18,,,,,124,5,5,,67,,,11,,,,24
393,TAK-994-1503,TAK-994,"A Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Oral TAK 994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Subjects",I,Reported,NS,18,19,50,0,31,19,5,105.56%,1,1,0,PRA,0,,2020-06-01,2020-08-10,,2020-09-23,2020-10-14,,2020-12-03,,2020-12-30,,,,,2021-01-28,,,,,29,5,5,,70,,,21,,,,27
486,C16009,Ninlaro,"Phase 1 Study of Oral MLN9708 to Assess Relative Bioavailability; Food Effect; Drug-Drug Interaction With Ketoconazole, Clarithromycin, or Rifampin; and Safety and Tolerability in Patients With Advanced Nonhematologic Malignancies or Lymphoma",I,Closed,Oncology,125,112,149,0,37,0,36,89.60%,6,1,0,ICON,0,,,2011-08-04,,,2011-11-11,,2015-03-09,2015-07-21,2016-12-31,,,,2016-12-31,2015-05-27,,,,2016-08-17,-584,5,5,,,,,,,,134,663
509,C13008,Entyvio,"A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn’s Disease",III,Closed,GI,"2,200","2,244",0,0,0,0,1502,102.00%,462,1,0,IQVIA,0,,,2008-06-26,,,2009-05-22,,2012-10-03,,2017-10-31,,,,,2018-01-29,,,,,90,5,5,,,,,,,,,1854
521,C16003,Ninlaro,"An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Relapsed and/or Refractory Multiple Myeloma",I,Closed,Oncology,63,0,0,0,2,0,0,0.00%,7,0,0,IQVIA,0,,,2009-05-18,,,2009-10-12,,2012-06-18,,2012-10-22,,,,2017-05-23,2013-03-25,,,,2017-06-30,154,5,5,,,,,,,,,126
522,C16004,Ninlaro,"An Open Label, Dose Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second Generation Proteasome Inhibitor, in Adult patients with Relapsed and Refractory Multiple Myeloma",I,Closed,Oncology,70,1,0,0,1,0,0,1.43%,6,0,0,0,0,,,2009-06-22,,,2009-11-30,,2012-09-24,2014-01-30,2014-09-20,,,,2014-09-20,2013-06-10,,,,2014-04-20,-467,5,5,,,,,,,,493,726
523,C16005,Ninlaro,"An Open-Label, Dose-Escalation Phase 1/2 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, Administered in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment",II,Closed,Oncology,61,65,0,0,0,0,64,106.56%,16,0,0,PPD,0,,,2010-05-26,,,2010-11-22,,2012-02-28,2013-10-20,2013-10-20,,,,2018-02-01,2014-04-07,,,,2018-03-02,169,5,5,,,,,,,,600,600
524,C16006,Ninlaro,"An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a  Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard  Care Regimen  of Melphalan and Prednisone in Patients With Newly Diagnosed  Multiple Myeloma Requiring Systemic Treatment",II,Closed,Oncology,61,61,0,0,0,0,27,100.00%,31,0,0,PPD,0,,,2010-12-22,,,2011-06-27,,2014-05-19,2015-10-19,2016-12-29,,,,,2017-05-03,,,,,125,5,5,,,,,,,,518,955
525,C16007,Ninlaro,"An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment",I,Closed,Oncology,32,27,41,0,14,0,0,84.38%,10,0,0,ICON,0,,,2010-08-31,,,2011-05-19,,2012-12-06,2013-08-01,2013-12-06,,,,2018-11-13,2014-02-12,,,,2018-12-06,68,5,5,,,,,,,,238,365
526,C16008,Ninlaro,"An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment",II,Closed,Oncology,60,64,0,0,0,0,54,106.67%,19,0,0,PPD,0,,,2011-02-28,,,2011-11-07,,2012-10-15,2013-10-14,2013-10-14,,,,2017-11-27,2014-02-28,,,,2017-12-19,137,5,5,,,,,,,,364,364
527,C15002,pevonedistat (TAK-924),"An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Lymphoma or Multiple Myeloma",I,Closed,Oncology,99,56,58,0,1,0,0,56.57%,14,1,0,PPD,0,,,2008-02-05,,,2008-06-30,,2013-04-02,2013-07-15,2013-07-15,,,,,2013-09-30,,,,,77,5,5,,,,,,,,104,104
528,C15001,pevonedistat (TAK-924),"An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Nonhematologic Malignancies",I,Closed,Oncology,89,62,62,0,0,0,1,69.66%,6,1,0,PPD,0,,,2007-12-11,,,2008-04-28,,2011-11-16,2012-02-15,2012-02-15,,,,,2012-03-16,,,,,30,5,5,,,,,,,,91,91
529,C15003,pevonedistat (TAK-924),"An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia",I,Closed,Oncology,72,72,79,0,7,0,3,100.00%,10,0,0,PPD,0,,,2009-04-13,,,2009-07-27,,2013-02-21,2013-08-25,2013-08-25,,,,,2013-10-28,,,,,64,5,5,,,,,,,,185,185
530,C15005,pevonedistat (TAK-924),"A Phase 1 , Open-Label, Dose- Escalation Study of MLN4924, a Novel Inhibiotr of Nedd8-Activating Enzyme, in Adult Patients with Melanoma",I,Closed,Oncology,66,37,37,0,0,0,3,56.06%,3,1,0,PPD,0,,,2009-09-15,,,2009-12-07,,2012-01-31,2012-05-22,2012-05-22,,,,,2012-08-17,,,,,87,5,5,,,,,,,,112,112
533,C25002,ADCETRIS,A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma,II,Closed,Oncology,42,36,40,0,5,0,0,85.71%,24,5,0,ICON,0,,,2011-07-11,,,2012-04-16,,2016-04-12,2016-10-12,2016-10-12,,,,2018-04-12,2016-12-03,,,,2018-05-02,52,5,5,,,,,,,,183,183
537,C25003,ADCETRIS,"A Randomized, Open-label, Phase 3 Trial of A+AVD versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma",III,Recruitment Complete,Oncology,23,"1,309",1546,0,236,0,0,5691.30%,258,223,0,ICON,0,,,2012-08-03,,,2012-11-19,,2016-01-13,2016-07-14,2017-04-20,,,,,2017-06-12,,,,,53,5,5,,,,,,,,183,463
538,C16010,Ninlaro,"A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma",III,Recruitment Complete,Oncology,41,838,1066,0,228,838,0,2043.90%,150,114,0,PPD,0,,,2012-02-21,,2012-08-13,2012-08-28,,2014-05-27,2015-12-27,2014-10-30,2017-11-13,2020-09-28,,,2015-01-15,2018-01-14,2020-11-06,,,77,5,5,,,,,15,,,579,156
540,C14012,Alisertib,"A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma",III,Closed,Oncology,354,155,3,0,62,274,0,43.79%,180,1,0,IQVIA,0,,,2011-07-25,,,2012-06-11,,2014-11-05,2015-06-30,2015-06-30,,,,,2015-09-15,,,,,77,5,5,,,,,,,,237,237
544,C27001,relugolix,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose, Inpatient and Outpatient Study in Healthy Men to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy for Testosterone Lowering of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist",I,Closed,Oncology,218,176,0,0,0,0,5,80.73%,2,0,0,Hammersmith Medicines Research,0,,,2011-09-29,,,2011-10-17,,2012-09-28,2012-12-18,2012-12-18,,,,,2013-01-17,,,,,30,5,5,,,,,,,,81,81
545,TAK-390MR_206,0,"A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years With Symptomatic Non-Erosive Gastroesophageal Reflux Disease",II,Closed,NonCore,104,0,0,0,0,0,0,0.00%,56,0,0,IQVIA,0,,2011-06-06,2012-02-09,,,2012-07-27,,2013-12-10,,2014-01-21,,,,,2014-03-13,,,,,51,5,5,,248,,,,,,,42
566,TBD-18831,relugolix,BA Study,I,Terminated,Oncology,50,0,0,0,0,0,0,0,1,0,0,TBD,0,,,2015-01-22,,,2015-03-24,,2015-03-24,2015-05-17,2015-05-17,,,,,2015-06-15,,,,,29,5,5,,,,,,,,54,54
578,TAK-931-1002,TAK-931,"An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 (CDC7) Inhibitor, in Adult Patients With Advanced Nonhematologic Tumors",I,All Activities Closed,Oncology,80,80,100,0,20,0,80,100.00%,2,0,0,PPD,0,,2015-11-17,2015-12-14,,,2016-03-30,,2019-08-06,2019-12-21,2019-12-20,,,,,2020-04-06,,,,,108,5,5,,27,,,,,,137,136
579,TAK-931-1003,TAK-931,TAK-931-1003 RBA-FE-PPI,I,All Activities Closed,Oncology,44,21,31,0,10,21,21,47.73%,4,0,0,PRA,0,,2018-05-07,2018-06-27,,,2019-04-10,,2019-08-05,2019-12-03,2019-12-03,,,,,2020-04-07,,,,,126,5,5,,51,,,,,,120,120
580,TAK-931-2001,TAK-931,Phase 2 Single Agent (88 pts),II,Reported,Oncology,142,101,126,0,25,0,101,71.13%,15,0,0,PRA,0,,2017-03-16,2017-07-14,,,2017-11-01,,2019-10-09,2020-08-24,2020-08-24,,,,,2020-11-06,,,,,74,5,5,,120,,,,,,320,320
597,C16047,Ninlaro,Ph 2 I-Dara Maintenance,II,Recruitment Complete,Oncology,60,61,97,0,36,0,43,101.67%,25,35,0,PRA,0,,2017-09-15,2017-11-30,,,2018-08-03,,2019-07-31,2020-01-31,2020-01-31,,,,,2020-03-17,,,,,46,5,5,,76,,,,,,184,184
602,C31008,sapanisertib,JNA PK/Safety SA and Combo w,I,Reported,Oncology,46,28,0,0,6,0,0,60.87%,4,0,0,IQVIA,0,,2017-04-06,2017-08-02,,,2018-01-31,,2019-04-19,2019-08-28,2019-08-28,,,,,2019-10-24,,,,,57,5,5,,118,,,,,,131,131
606,C34004,TAK-659,C34004 Phase 2 Single Agent (R/R DLBCL) (82 pts),II,Completed,Oncology,122,49,84,0,35,0,45,40.16%,50,0,0,PRA,0,,2016-03-18,2017-03-01,,,2017-10-23,,2018-08-02,2019-01-31,2019-01-31,,,,2020-03-20,2019-04-11,,,,2020-04-21,70,5,5,,348,,,,,,182,182
608,C34003,TAK-659,A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors,II,Closed,Oncology,48,41,64,0,23,0,41,85.42%,25,1,0,PRA,0,,2015-12-14,2016-04-06,,,2016-08-25,,2018-07-25,2018-10-15,2018-10-15,,,,,2019-05-07,,,,,204,5,5,,114,,,,,,82,82
609,C34005,TAK-659,C34005 Phase 1b Multi-Arm Combo study (100pts),II,Recruitment Complete,Oncology,55,43,70,0,27,0,0,78.18%,15,0,0,PRA,0,,2016-03-31,2016-06-07,,,2017-06-15,,2018-11-20,2020-07-27,2020-07-27,,,,,2020-09-04,,,,,39,5,5,,68,,,,,,615,615
630,C25010,ADCETRIS,"A Phase 2, Single-Arm, Open-label
Study of Brentuximab Vedotin in Chinese Patients With
Relapsed/Refractory CD30-Positive Hodgkin Lymphoma
(HL) or Systemic Anaplastic Large Cell Lymphoma
(sALCL)",II,Reported,Oncology,30,39,43,0,4,39,39,130.00%,9,0,0,IQVIA,0,,,2016-04-21,,2016-11-07,2016-11-23,,2017-07-25,2018-07-03,2018-08-02,,,,2020-02-03,2018-09-12,,,,2020-06-26,41,5,5,,,,,16,,,343,373
657,Pevonedistat-1014,pevonedistat (TAK-924),Evaluation of Effects of Pevonedistat on the QTc Interval in Patients with Advanced Solid Tumors,I,Recruitment Complete,Oncology,45,44,68,0,24,0,3,97.78%,8,6,0,PRA,0,,,2017-06-29,,,2018-03-13,,2018-12-17,2019-05-16,2019-01-07,,,,2021-06-21,2019-05-06,,,,,-777,5,5,,,,,,,,150,21
660,Pevonedistat-1013,pevonedistat (TAK-924),Human ADME Study,I,Closed,Oncology,8,8,13,0,5,0,1,100.00%,2,0,0,PRA,0,,,2016-11-29,,,2017-05-25,,2018-02-01,2018-07-02,2018-02-09,,,,2018-11-05,2018-04-09,,,,2018-12-10,59,5,5,,,,,,,,151,8
674,Leuprorelin-4001,LEUPLIN (leuprorelin acetate),"An Open label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Preccocious Puberty",IV,Closed,NonCore,300,307,340,0,33,0,23,102.33%,12,0,0,Hangzhou Tigermed Consulting,0,,2015-01-06,2014-11-03,,2015-07-28,2015-08-11,,2016-12-30,,2018-11-19,,,,,2019-01-17,,,,,59,5,5,,-64,,,14,,,,689
675,TAK-390MR-1001,"DEXILANT (dexlansoprazole, MR)","A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Two Part Crossover Study to Compare the Bioavailability of Dexlansoprazole from Dexlansoprazole Delayed Release Capsules 30 mg and 60 mg Manufactured by Takeda Oranienburg Relative to Reference Dexlansoprazole Delayed Release Capsules 30 mg and 60 mg Manufactured by Takeda Osaka in Healthy Subjects",I,Closed,NonCore,104,116,218,0,100,0,16,111.54%,1,0,0,PRA,0,,2016-03-16,2016-10-31,,2017-04-24,2017-05-20,,2017-06-24,,2017-07-14,,,,,2017-08-16,,,,,33,5,5,,229,,,26,,,,20
679,TAK-041-1001,TAK-041,"A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Ascending Oral Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-041 in Healthy Subjects",I,All Activities Closed,NS,114,114,380,0,276,0,3,100.00%,1,1,0,PPD,0,,2016-10-31,2016-04-01,,2016-05-09,2016-06-27,,2019-07-09,,2019-09-22,,,,,2019-11-14,,,,,53,5,5,,-213,,,49,,,,75
683,C31006,sapanisertib,An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy,II,Recruitment Complete,Oncology,141,141,191,0,50,0,141,100.00%,55,0,0,GEICAM,0,,2015-07-22,2016-02-10,,,2016-08-12,,2018-05-14,2019-01-31,2019-11-29,,,,,2020-04-06,,,,,129,5,5,,203,,,,,,262,564
684,Vortioxetine-4001,Trintellix (vortioxetine),"A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg/day vs. Paroxetine 20 mg/day on Sexual Functioning in Healthy Subjects",IV,Closed,NS,352,361,591,0,230,0,67,102.56%,16,0,0,IQVIA,0,,2016-02-16,2016-07-13,,2016-11-21,2016-12-06,,2017-04-24,,2017-06-09,,,,,2017-07-31,,,,,52,5,5,,148,,,15,,,,46
693,Vedolizumab-1015,Entyvio,"An open-label, dose-finding study of vedolizumab intravenous (IV) vedolizumab plus standard of care for graft-versus-host disease (GvHD) prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)",II,Closed,GI,24,24,31,0,7,0,6,100.00%,4,0,0,PRA,0,,2015-10-06,2015-12-09,,,2016-06-29,,2017-06-22,,2018-07-10,,,,,2018-08-29,,,,,50,5,5,,64,,,,,,,383
694,Vedolizumab-1014,Entyvio,"Open-Label, Single-Center, Phase 1 Study to Determine the Pharmacokinetics of Single Intravenous Dose of Vedolizumab 300 mg in Healthy Adult Chinese Subjects",I,Closed,GI,16,16,92,0,76,0,0,100.00%,1,0,0,PRA,0,,2015-03-20,2015-07-10,,2018-03-05,2018-03-20,,2018-03-22,,2018-07-26,,,,,2018-11-14,,,,,111,5,5,,112,,,15,,,,126
696,Vedolizumab-3034,Entyvio,A Phase 3 Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Patients with Moderately to Severely Active Crohn’s Disease Protocol,III,Recruitment Complete,GI,204,215,346,0,131,215,108,105.39%,30,0,0,IQVIA,0,,2015-03-19,2015-07-08,,2017-08-03,2017-08-24,,2018-12-20,,2019-02-28,,,,,2019-06-13,,,,,105,5,5,,111,,,21,,,,70
699,TAK-071-1001,TAK-071,"A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects",I,Terminated,NS,186,177,363,0,184,0,1,95.16%,1,1,0,PPD,0,,2015-11-30,2016-04-06,,2016-05-05,2016-05-18,,2017-05-24,,2017-06-08,,,,,2017-08-14,,,,,67,5,5,,128,,,13,,,,15
705,TAK-906-1003,TAK-906,"A Fixed Sequence, Open-Label, 2-Period, Crossover Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Single-Dose Pharmacokinetics of Oral TAK 906 in Healthy Adult Subjects.",I,Closed,GI,12,12,39,0,23,0,1,100.00%,1,0,0,PRA,0,,2017-02-22,2017-03-21,,2017-06-05,2017-06-23,,2017-06-23,,2017-07-11,,,,,2017-08-18,,,,,38,5,5,,27,,,18,,,,18
707,Pevonedistat-1015,pevonedistat (TAK-924),DDI Study,I,Reported,Oncology,20,20,26,0,6,0,20,100.00%,4,0,0,PRA,0,,,2017-11-29,,,2018-08-27,,2019-04-29,,2019-05-10,,,,2020-04-29,2019-07-16,,,,2020-09-04,67,5,5,,,,,,,,,11
711,TAK-906-1007,TAK-906,ADME Study of TAK-906,I,Completed,GI,6,6,19,0,0,0,0,100.00%,1,0,0,Celerion,0,,2020-03-09,2020-04-03,,2020-06-17,2020-07-30,,2020-09-01,,2020-09-29,,,,,2020-10-30,,,,,31,5,5,,25,,,43,,,,28
718,TAK-906-1006,TAK-906,Phase 1.6 DDI PPI,I,Closed,GI,12,12,12,0,0,0,0,100.00%,1,0,0,Celerion,0,,2018-12-13,2019-02-07,,2019-02-27,2019-03-13,,2019-03-20,,2019-03-30,,,,,2019-05-04,,,,,35,5,5,,56,,,14,,,,10
721,TAK-954-2003,TAK-954,"Effect of TAK-954, a selective 5-HT4 receptor agonist on gastrointestinal and colonic transit and pharmacokinetics in patients with diabetic or idiopathic gastroparesis and previously documented delay in stomach emptying.",II,Closed,GI,48,36,44,0,9,37,2,75.00%,1,0,0,PRA,0,,2017-04-28,2017-08-02,,2018-01-02,2018-01-06,,2019-06-04,,2019-07-12,,,,,2019-08-27,,,,,46,5,5,,96,,,4,,,,38
722,AP26113-11-101,Alunbrig,"101 Ph1/2 Safety, PK, Tolerability",II,All Activities Closed,Oncology,137,137,171,0,34,0,45,100.00%,10,0,0,TBD,0,,,2011-06-27,,,2011-09-20,,2014-07-08,2019-06-12,2020-02-11,,,,,2020-07-29,,,,,169,5,5,,,,,,,,1800,2044
723,AP26113-13-201,Alunbrig,"ALTA Ph2 Multicenter, Randomized Study",II,Closed,Oncology,222,222,269,0,47,0,167,100.00%,80,0,0,PRA,0,,2013-06-27,2013-06-27,,,2014-06-09,,2015-09-21,,2016-11-14,,,,2020-02-27,2016-12-23,,,,2020-06-05,39,5,5,,0,,,,,,,420
724,AP32788-15-101,Mobocertinib (TAK-788),Ph 1/2 Safety/PK,II,Recruiting,Oncology,336,226,276,0,51,186,183,67.26%,95,28,0,PRA,0,,,2015-11-21,,,2016-06-16,,,,2020-05-29,2020-11-01,,,,2020-09-04,2021-01-08,,,,98,5,5,,,,,,,,,
726,AP26113-15-107,Alunbrig,107 Hepatic Impairment,I,Closed,Oncology,1,0,0,0,0,0,0,0.00%,1,0,0,INC Research,0,,,2016-02-27,,,2016-05-19,,2016-11-26,2016-12-04,2016-12-04,,,,,2017-06-26,,,,,204,5,5,,,,,,,,8,8
728,AP26113-15-108,Alunbrig,108 Renal Impairment,I,Closed,Oncology,1,0,0,0,0,0,0,0.00%,1,0,0,INC Research,0,,,2016-02-27,,,2016-05-26,,2016-10-27,2016-11-03,2016-11-03,,,,,2017-06-26,,,,,235,5,5,,,,,,,,7,7
729,AP26113-13-301,Alunbrig,ALTA-1L Ph3 Brigatinib vs Crizotinib,III,Completed,Oncology,270,275,311,0,36,45,126,101.85%,150,18,0,PRA Health Sciences,0,,,2015-10-22,,,2016-06-09,,2017-08-15,2020-05-19,2018-02-19,2019-06-28,,,2020-12-21,2018-06-21,2019-09-21,,,2021-03-02,122,5,5,,,,,,,,1008,188
730,Brigatinib-2001,Alunbrig,"A Single-arm, Multi-center, Phase 2 Study of Brigatinib in Japanese  Patients with ALK-positive, Non-Small Cell Lung Cancer (NSCLC)",II,Reported,Oncology,80,72,79,0,7,0,45,90.00%,1,0,0,TBD,0,,2017-06-23,2017-11-02,,,2018-02-21,,2019-04-12,,2019-09-03,,,,,2019-11-12,,,,,70,5,5,,132,,,,,,,144
735,TAK-831-1005,TAK-831,"A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Subjects",I,Closed,NS,48,50,126,0,76,50,3,104.17%,1,0,0,PRA,0,,2017-05-31,2017-06-08,,2017-08-03,2017-08-03,,2018-07-13,,2018-09-09,,,,,2018-10-02,,,,,23,5,5,,8,,,0,,,,58
736,Actovegin-3001,Actovegin (deproteinized hemoderivative of calf blood),"A Randomized, Multi-center, Parallel Group, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Subjects with Peripheral Arterial Occlusive Disease Fontaine Stage IIB",III,All Activities Closed,NonCore,366,366,387,0,21,0,3,100.00%,20,0,0,Atlant,0,,2017-01-18,2017-12-21,,2018-04-30,2018-08-03,,2019-03-05,,2019-08-20,,,,,2019-11-22,,,,,94,5,5,,337,,,95,,,,168
737,VedolizumabSC-1018,Entyvio SC,"A Phase 1, Open-Label, Randomized, Parallel Group Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Needle Safety Device in Healthy Subjects",I,Closed,GI,102,102,210,0,108,0,1,100.00%,1,0,0,Celerion,0,,,2017-12-18,,2018-02-18,2018-03-16,,2018-04-10,,2018-09-21,,,,,2018-10-05,,,,,14,5,5,,,,,26,,,,164
738,Brigatinib-1001,Alunbrig,"A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam
in Patients With ALK-Positive or ROS1-Positive Solid Tumors",I,Recruitment Complete,Oncology,20,24,32,0,8,0,24,120.00%,14,14,0,PRA,0,,2017-09-20,2017-11-14,,,2019-07-04,,2020-02-25,2020-03-25,2020-03-25,,,,,2020-10-12,,,,,201,5,5,,55,,,,,,29,29
739,TIMP-GLIA-5001,TAK-101,Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge,0,All Activities Closed,GI,20,16,24,0,8,16,2,80.00%,2,0,0,PRA,0,,2017-08-01,2017-10-11,,2018-04-24,2018-06-25,,2019-03-20,,2019-04-29,,,,,2019-09-20,,,,,144,5,5,,71,,,62,,,,40
740,Ponatinib-3001,Iclusig,"A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)",III,Recruiting,Oncology,230,174,246,0,69,174,80,75.65%,120,116,0,PRA,0,,2017-11-14,2018-05-24,,,2019-01-10,,,,2021-02-17,,,,,2021-05-19,,,,,91,5,5,,191,,,,,,,
747,AP24534-10-201,Iclusig,PACE: Phase 2,II,Reported,Oncology,449,244,0,0,0,0,0,54.34%,42,0,0,INC Research,0,,,2010-06-01,,,2010-09-30,,2011-10-31,2015-10-12,2015-10-10,,,,2019-01-17,2017-03-31,,,,2019-03-28,538,5,5,,,,,,,,1442,1440
748,AP24534-11-106,Iclusig,Phase 1/2 Study in Japanese Patients,II,Reported,Oncology,40,0,0,0,0,0,0,0,1,0,0,CMIC,0,,,2012-04-30,,,2012-08-14,,2013-09-30,2015-10-07,2015-11-14,,,,2018-08-02,2014-11-17,,,,2018-10-26,-362,5,5,,,,,,,,737,775
749,AP24534-14-203,Iclusig,OPTIC: Phase 2 CML Efficacy/Safety,II,Recruitment Complete,Oncology,276,283,371,0,92,291,140,102.54%,150,60,0,PRA,0,,,2015-02-02,,,2015-08-06,,2019-05-15,2021-05-15,2019-07-20,2020-05-31,,,2021-06-15,2019-09-10,2020-12-21,,,,52,5,5,,,,,,,,731,66
752,TAK-653-1003,TAK-653,"A randomized, double blind, placebo-controlled, single dose, cross-over study to evaluate the pharmacodynamic aspects, tolerability and safety of TAK-653 in healthy volunteers assessing responses evoked by transcranial magnetic stimulation (TMS).",I,All Activities Closed,NS,24,24,24,0,0,0,0,100.00%,1,0,0,PRA,0,,2018-10-19,2018-11-26,,2019-01-21,2019-02-11,,2019-05-30,,2019-06-14,,,,,2019-07-15,,,,,31,5,5,,38,,,21,,,,15
753,TBD-1-30EP0F,TAK-418,BCH KS Natural Chip Seq,0,Terminated,NS,40,0,0,0,0,0,0,0,1,0,0,TBD,0,,2018-06-08,2018-08-06,,2018-10-29,2018-11-14,,2019-02-06,,2019-02-07,,,,,2019-02-26,,,,,19,5,5,,59,,,16,,,,1
765,TAK-994-1001,TAK-994,"A Combined Single Rising Dose and  Multiple Rising Dose Study to Access the Safety, Tolerability, Pharmacodynamics and Pharmacodynamics  of TAK-994 in Normal Healthy Volunteers and Patients with Narcolepsy",I,Completed,NS,160,121,354,0,234,0,3,75.63%,2,0,0,PRA,0,,2019-02-04,2019-03-18,,2019-05-01,2019-05-22,,2020-03-04,,2020-03-29,,,,,2020-06-24,,,,,87,5,5,,42,,,21,,,,25
828,TAK-954-1009,TAK-954,"A Double-Blind, Placebo-Controlled, Multiple Ascending, 3 Period, Incomplete Block Design Trial to Investigate the Safety, Tolerability and Pharmacokinetics of TAK 954 Administered as a 60-minute IV Infusion to Healthy Adult Participants",I,Closed,GI,6,6,18,0,0,0,0,100.00%,1,0,0,Celerion,0,,2018-12-16,2019-02-04,,2019-03-06,2019-03-24,,2019-03-24,,2019-05-12,,,,,2019-06-14,,,,,33,5,5,,50,,,18,,,,49
839,TAK-925-1009,TAK-925,"An Open-Label, Trial to Evaluate the Effect of the Cobicistat on two Single-Doses Pharmacokinetics of Oral TAK-925 in Healthy Adult Subjects",I,All Activities Closed,NS,16,16,54,0,0,0,0,100.00%,1,0,0,Celerion,0,,2019-06-25,2019-08-16,,2019-10-11,2019-10-11,,2019-11-12,,2019-12-03,,,,,2020-01-24,,,,,52,5,5,,52,,,0,,,,21
853,MT203-2004,MT203,A Phase 2 Exploratory Study of Namilumab vs Anti-Tumor Necrosis Factor in Patients With Early Rheumatoid Arthritis Inadequately Responding to Methotrexate,II,Terminated,NonCore,36,7,0,0,8,0,0,19.44%,15,0,0,IQVIA,0,,2014-06-19,2014-08-18,,2015-04-08,2015-04-29,,2016-01-14,,2016-11-01,,,,,2016-12-19,,,,,48,5,5,,60,,,21,,,,292
877,AP24534-15-303,Iclusig,OPTIC-2L: Phase 3 Ponatinib vs Nilotinib,III,Recruitment Complete,Oncology,44,44,60,0,16,0,3,100.00%,90,0,0,INC Research,0,,,2015-10-12,,2016-01-28,2016-02-11,,2017-10-24,2018-10-23,2020-11-26,,,,,2021-03-22,,,,,116,5,5,,,,,14,,,364,1129
880,TAK-788-1005,Mobocertinib (TAK-788),"A Phase 1, Randomized, 2-Period, 2-Sequence, Crossover Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics in Healthy Adult Subjects",I,Reported,Oncology,14,14,25,0,9,0,0,100.00%,1,0,0,Celerion,0,,2019-09-10,2020-06-10,,,2020-07-01,,2020-07-01,2020-07-21,2020-07-21,,,,,2020-09-14,,,,,55,5,5,,274,,,,,,20,20
881,TAK-788-1002,Mobocertinib (TAK-788),Human ADME – Absolute BA,I,Completed,Oncology,6,7,18,0,0,0,0,116.67%,1,0,0,Celerion,0,,2018-07-13,2018-12-19,,,2019-01-31,,2019-02-01,2019-03-11,2019-03-11,,,,,2019-08-15,,,,,157,5,5,,159,,,,,,38,38
883,TAK-788-1004,Mobocertinib (TAK-788),Induction w/ Sensitive CYP3A Substrate,I,Recruitment Complete,Oncology,26,26,36,0,10,0,23,100.00%,8,0,0,PRA,0,,2018-11-16,2019-02-18,,,2020-01-06,,2020-11-16,,2020-12-17,,,,,2021-03-15,,,,,88,5,5,,94,,,,,,,31
905,TAK-788-1006,Mobocertinib (TAK-788),DDI w/ Strong CYP3A Inh. & Inducer,I,All Activities Closed,Oncology,28,24,28,0,0,0,0,85.71%,1,0,0,Celerion,0,,2019-02-28,2019-04-23,,,2019-05-21,,2019-07-05,2019-08-16,2019-08-16,,,,,2019-09-25,,,,,40,5,5,,54,,,,,,42,42
909,TBD-1-304JYV,TAK-951,A Phase 0 pilot study in healthy subjects to assess the effects of an NK-1 receptor antagonist compared to placebo on nausea of vomiting after an apomorphine challenge.,0,Completed,GI,14,14,22,0,8,0,0,100.00%,1,0,0,Parexel,0,,2018-08-27,2018-10-01,,2018-10-22,2018-11-12,,2018-12-06,,2018-12-06,,,,,2019-01-31,,,,,56,5,5,,35,,,21,,,,0
912,TAK-935-2008,soticlestat (TAK-935),"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pain Syndrome- Takeda study",II,Completed,NS,24,24,59,0,35,24,9,100.00%,6,0,0,PRA,0,,2018-11-20,2019-01-31,,2019-07-23,2019-07-31,,2020-03-16,,2020-10-21,,,,,2021-02-16,,,,,118,5,5,,72,,,8,,,,219
918,TAK-831-1008,TAK-831,ADME TAK-831,I,Reported,NS,6,6,17,0,0,0,0,100.00%,1,0,0,Celerion,0,,2019-08-29,2019-10-29,,2020-02-25,2020-02-26,,2020-02-27,,2020-04-01,,,,,2020-09-14,,,,,166,5,5,,61,,,1,,,,34
919,C16011,Ninlaro,"A Phase 3, Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis",III,Recruitment Complete,Oncology,248,177,282,0,105,177,0,71.37%,74,30,0,PPD,0,,,2012-06-01,,,2013-01-02,,2019-05-31,2020-05-30,2019-02-20,,,,,2019-04-23,,,,,62,5,5,,,,,,,,365,-100
920,LuAA21004_402,Trintellix (vortioxetine),"A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder",IV,Closed,NS,"1,100",995,0,0,712,0,0,90.45%,65,0,0,IQVIA,0,,2014-08-27,2014-10-27,,2015-02-10,2015-02-18,,2018-04-30,,2019-04-25,,,,,2019-06-25,,,,,61,5,5,,61,,,8,,,,360
921,Vonoprazan-2001,vonoprazan,"A randomized, double-blind, proof-of-concept, phase 2 study to evaluate the efficacy and safety of once daily oral vonoprazan 20mg or vonoprazan 40mg compared to esomeprazole 40mg for the treatment of subjects With symptomatic gastro oesophageal reflux disease who have a partial response following treatment with a high dose of proton pump inhibitor",II,Closed,GI,214,120,0,0,151,0,0,56.07%,38,0,0,IQVIA,0,,2014-12-19,2015-12-04,,2016-04-21,2016-07-14,,2018-09-07,,2018-10-05,,,,,2019-02-20,,,,,138,5,5,,350,,,84,,,,28
1002,C16013,Ninlaro,A Phase 1 Pharmacokinetic and Tolerability Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients with Relapsed and/or Refractory Multiple Myeloma,I,Closed,Oncology,24,43,53,0,10,0,2,179.17%,8,8,0,PPD,0,,,2012-02-10,,,2012-12-17,,2014-06-17,2016-01-31,2014-07-14,,,,2017-04-04,2014-10-02,,,,2017-05-15,80,5,5,,,,,,,,593,27
1005,INK128-001,sapanisertib,"A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects with Advanced Malignancies Followed by an Expansion in Subjects with Measurable Disease",I,Closed,Oncology,170,198,273,0,75,0,0,116.47%,16,17,0,Synteract,0,,,2009-11-03,,,2009-12-22,,2015-01-30,2015-10-02,2015-10-02,,,,2019-02-07,2016-03-04,,,,2019-05-09,154,5,5,,,,,,,,245,245
1006,INK128-002,sapanisertib,"A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects with Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia",I,Closed,Oncology,60,39,39,0,0,0,4,65.00%,12,1,0,Synteract,0,,,2010-04-07,,,2010-11-19,,2012-10-25,,2013-05-29,,,,2016-12-02,2013-06-25,,,,,27,5,5,,,,,,,,,216
1007,INK128-003,sapanisertib,"A Phase I, Open Label, Dose Escalation Study of Oral Administration of INK128 in Combination with Paclitaxel, with/without Trastuzumab, in Subjects with Advanced Solid Malignancies",I,Closed,Oncology,95,69,107,0,38,0,11,72.63%,3,4,0,Sarah Cannon Research Institut,0,,,2011-01-12,,,2011-03-01,,2013-07-23,2016-07-29,2014-05-29,,,,2017-09-15,2014-07-30,,,,2018-01-30,62,5,5,,,,,,,,1102,310
1009,C16014,Ninlaro,"A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma",III,Recruitment Complete,Oncology,60,748,1148,0,400,748,0,1246.67%,200,127,0,PPD,0,,,2013-02-14,,,2013-05-17,,2015-12-31,2018-03-31,2018-02-15,2019-12-02,,,,2018-03-27,2020-01-22,,,,40,5,5,,,,,,,,821,777
1016,C16015,Ninlaro,Phase 1/1b Pharmacokinetics Study of Oral MLN9708 in Patients With Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors With Normal Renal Function or Severe Renal Impairment,I,Closed,Oncology,40,40,0,0,0,0,39,100.00%,10,0,0,ICON,0,,,2012-10-23,,,2013-09-24,,2015-02-17,2015-06-20,2015-03-03,,,,2016-11-18,2015-04-09,,,,2017-01-25,37,5,5,,,,,,,,123,14
1017,C16017,Ninlaro,"An Open-Label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma",II,Closed,Oncology,44,29,0,0,0,0,26,65.91%,26,0,0,PPD,0,,,2013-05-23,,,2013-11-18,,2015-11-19,2016-03-19,2017-03-23,,,,2017-03-23,2017-05-10,,,,2017-05-10,48,5,5,,,,,,,,121,490
1018,C15009,pevonedistat (TAK-924),"A Phase 1B, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients with Acute Myelogenous Leukemia Who are 60 Years or Older",I,Closed,Oncology,64,64,78,0,14,0,63,100.00%,4,8,0,PPD,0,,,2012-10-11,,,2013-04-15,,2015-11-30,2016-06-30,2016-06-30,,,,2018-05-17,2016-09-13,,,,2018-07-10,75,5,5,,,,,,,,213,213
1019,C16016,Ninlaro,"A Phase 1 Study of [14C]-MLN9708 to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients with Advanced Solid Tumors or Lymphoma",I,Closed,Oncology,6,7,12,0,5,0,2,116.67%,1,1,0,ICON,0,,,2012-11-12,,,2014-03-19,,2014-11-12,2015-03-21,2015-02-20,,,,2016-01-21,2015-02-28,,,,,8,5,5,,,,,,,,129,100
1028,C25001,ADCETRIS,"A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma",III,Closed,Oncology,136,132,236,0,104,0,0,97.06%,52,10,0,ICON,0,,,2012-01-24,,,2012-08-13,,2015-07-31,2016-02-28,2016-05-30,,,,2018-07-06,2016-07-20,,,,2018-10-17,51,5,5,,,,,,,,212,304
1029,C28001,TAK-580,"An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma",I,Closed,Oncology,150,122,1,0,12,89,0,81.33%,17,0,0,IQVIA,0,,,2011-07-07,,,2011-09-15,,2016-09-30,2017-04-11,2017-04-11,,,,,2017-06-22,,,,,72,5,5,,,,,,,,193,193
1034,MA25101,ADCETRIS,An Observational Cohort Study of the Safety of Brentuximab Vedotin in the Treatment of Relapsed or Refractory CD30+ Hodgkin Lymphoma and Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma,IV,All Activities Closed,Oncology,0,22,0,0,0,4,0,0,0,0,0,IQVIA,0,,,2012-06-14,,,2013-06-26,,2018-01-09,2018-08-22,2018-09-21,,,,,2018-11-15,,,,,55,5,5,,,,,,,,225,255
1037,C25006,ADCETRIS,"A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma",IV,Recruitment Complete,Oncology,49,50,62,0,12,50,0,102.04%,40,0,0,IQVIA,0,,,2012-11-29,,,2014-01-30,,2019-10-10,2020-05-01,2021-05-04,,,,,2021-06-25,,,,,52,5,5,,,,,,,,204,572
1039,C16001,Ninlaro,"An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies",I,Closed,Oncology,116,116,137,0,22,0,35,100.00%,7,0,0,Dobbs Consulting,0,,,2008-12-15,,,2009-03-04,,2012-01-10,2012-04-20,2012-04-20,,,,,2012-05-24,,,,,34,5,5,,,,,,,,101,101
1040,C16002,Ninlaro,"An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients with Lymphoma",I,Closed,Oncology,34,31,44,0,13,0,6,91.18%,6,4,0,Dobbs Consulting,0,,,2009-02-26,,,2009-08-20,,2012-10-01,2014-10-20,2014-10-20,,,,2014-10-20,2014-12-20,,,,,61,5,5,,,,,,,,749,749
1043,C15010,pevonedistat (TAK-924),"A Phase 1b, Open-Label, Dose-Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel, in Patients with Solid Tumors",I,Closed,Oncology,64,48,0,0,16,0,0,75.00%,6,0,0,IQVIA,0,,,2013-03-08,,,2013-07-01,,2015-05-04,2016-02-15,2016-02-15,,,,2018-05-21,2016-09-12,,,,2018-06-26,210,5,5,,,,,,,,287,287
1045,C32001,sapanisertib,"A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3Ka Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies",I,Closed,Oncology,101,85,0,0,16,2,0,84.16%,10,0,0,IQVIA,0,,,2013-03-07,,,2013-07-03,,2016-09-26,2017-03-24,2017-03-24,,,,2018-06-28,2017-04-19,,,,2018-06-29,26,5,5,,,,,,,,179,179
1046,C16018,Ninlaro,A Phase 1 Pharmacokinetic Study of Oral MLN9708 in Patients with Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction,I,Closed,Oncology,45,48,0,0,0,0,48,106.67%,4,0,0,PPD,0,,,2013-04-19,,,2013-08-27,,2015-01-22,2015-03-25,2015-03-25,,,,2015-03-25,2015-05-19,,,,,55,5,5,,,,,,,,62,62
1048,C25007,ADCETRIS,A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy,IV,All Activities Closed,Oncology,60,61,0,0,7,8,0,101.67%,21,0,0,IQVIA,0,,,2013-07-11,,,2014-03-21,,2015-03-11,2015-10-11,2016-03-24,,,,2020-03-11,2016-05-23,,,,2020-04-10,60,5,5,,,,,,,,214,379
1052,C34001,TAK-659,"An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies",I,Recruitment Complete,Oncology,182,144,1,0,51,0,0,79.12%,16,0,0,IQVIA,0,,,2013-09-10,,,2013-12-12,,2018-04-09,2018-07-13,2018-07-13,,,,,2019-02-26,,,,,228,5,5,,,,,,,,95,95
1053,C16020,Ninlaro,"An Open-Label, Phase 2 Study to Evaluate the Oral Combination of MLN9708 With Cyclophosphamide and Dexamethasone In Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment",II,Closed,Oncology,148,148,0,0,0,0,0,100.00%,26,0,0,PPD,0,,,2013-07-23,,,2014-03-12,,2015-05-20,2016-12-08,2016-06-29,,,,2018-06-29,2016-08-24,,,,2018-07-30,56,5,5,,,,,,,,568,406
1054,C31001,sapanisertib,A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant,II,Closed,Oncology,118,86,0,0,39,3,0,72.88%,40,0,0,IQVIA,0,,2013-06-27,2013-09-09,,,2014-02-18,,2018-01-05,2018-07-03,2018-07-03,,,,,2018-09-07,,,,,66,5,5,,74,,,,,,179,179
1114,C27002,relugolix,"A Phase 2 Randomized Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of the oral GnRH Antagonist TAK-385, together with a Leuprorelin Observational Cohort,  in Patients with Prostate Cancer",II,Closed,Oncology,125,48,0,0,27,138,0,38.40%,25,0,0,IQVIA,0,,,2013-12-03,,,2014-04-17,,2015-02-19,2016-08-21,2016-03-31,,,,2017-03-07,2016-06-14,,,,2017-05-24,75,5,5,,,,,,,,549,406
1116,C27003,relugolix,"Phase 2, Randomized, Open-label, Parallel Group Study of the Safety and Efficacy for Medical Castration of the Oral GnRH antagonist, TAK-385, in Patients with Moderate Risk Localized Prostate Cancer Who Require NeoAdjuvant / Adjuvant Therapy to xRT (EBMT or IMRT)",II,Closed,Oncology,100,80,0,0,17,108,0,80.00%,28,0,0,IQVIA,0,,,2014-01-17,,,2014-06-10,,2015-03-30,2015-12-13,2015-12-14,,,,,2016-03-28,,,,,105,5,5,,,,,,,,258,259
1122,C15011,pevonedistat (TAK-924),"A Phase 1 Study to Evaluate the Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",I,Closed,Oncology,52,51,0,0,0,0,11,98.08%,4,0,0,PPD,0,,,2014-02-03,,,2014-05-13,,2016-07-18,2017-01-18,2017-06-05,,,,,2017-08-28,,,,,84,5,5,,,,,,,,184,322
1123,C27005,relugolix,"A Phase 1, Open-label, Drug-drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Fluconazole or Atorvastatin on the Pharmacokinetics of a Single Oral Dose of TAK-385 in Healthy Subjects",I,Closed,Oncology,40,40,90,0,50,0,1,100.00%,1,2,0,In-House,0,,,2014-01-06,,,2014-03-29,,2014-03-29,2014-04-19,2014-04-19,,,,,2014-05-27,,,,,38,5,5,,,,,,,,21,21
1124,C25004,ADCETRIS,"An open-label study of brentuximab vedotin + Adriamycin®, vinblastine, and dacarbazine in paediatric patients with advanced stage newly diagnosed Hodgkin lymphoma",II,Recruitment Complete,Oncology,67,59,63,0,4,0,59,88.06%,28,0,0,IQVIA,0,,,2016-08-12,,,2017-09-11,,2019-09-25,2020-04-15,2020-12-18,,,,,2021-01-28,,,,,41,5,5,,,,,,,,203,450
1125,C16021,Ninlaro,"A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation",III,Recruitment Complete,Oncology,706,727,1000,0,284,716,0,102.97%,229,166,0,PPD,0,,,2014-09-15,,,2015-04-23,,2018-10-08,,2019-08-12,2020-10-15,,,,2019-09-18,2020-11-25,,,,37,5,5,,,,,,,,,308
1126,C26002,TAK-264,A phase 2 trial of MLN0264 in previously treated patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C (GCC),II,Terminated,Oncology,38,14,0,0,21,7,0,36.84%,35,0,0,IQVIA,0,,,2014-02-27,,,2014-08-05,,2015-06-02,2015-10-23,2015-10-23,,,,,2016-03-28,,,,,157,5,5,,,,,,,,143,143
1127,C26003,TAK-264,A phase 2 trial of MLN0264 in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC),II,Terminated,Oncology,43,18,1,0,48,0,0,41.86%,35,0,0,IQVIA,0,,,2014-02-27,,,2014-10-14,,2015-06-30,2015-11-13,2015-11-13,,,,,2016-04-27,,,,,166,5,5,,,,,,,,136,136
1128,C16010CCS,Ninlaro,"A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma",III,Recruitment Complete,Oncology,115,115,146,0,31,0,7,100.00%,11,0,0,PPD,0,,,2013-11-27,,,2014-05-06,,2015-05-04,2016-11-21,2015-07-12,,,,,2015-08-19,,,,,38,5,5,,,,,,,,567,69
1130,C26004,TAK-264,A Phase 1/2 Trial of MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal (GI) Carcinoma (Phase 1) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (Phase 2) Expressing Guanylyl Cyclase C (GCC),II,Terminated,Oncology,95,12,12,0,0,0,12,12.63%,21,0,0,IQVIA,0,,,2014-05-15,,,2015-01-19,,2015-06-11,2015-10-08,2015-10-08,,,,,2016-01-12,,,,,96,5,5,,,,,,,,119,119
1132,C34002,TAK-659,"An Open Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK 659  in Adult Patients with Relapsed or Refractory AML",II,Closed,Oncology,106,39,1,0,19,12,0,36.79%,15,0,0,IQVIA,0,,,2014-09-24,,,2015-04-02,,2018-03-29,2018-09-27,2018-09-27,,,,,2019-04-23,,,,2019-07-30,208,5,5,,,,,,,,182,182
1137,C31004,sapanisertib,"A phase 2, randomized study of MLN0128 (a dual TORC1/2 inhibitor), MLN0128 + MLN1117 (a PI3Ka inhibitor), weekly paclitaxel, or the combination of weekly paclitaxel and MLN0128 in women with advanced, recurrent, or persistent endometrial cancer",II,Reported,Oncology,242,245,411,0,166,245,245,101.24%,77,0,0,PRA,0,,2014-04-09,2015-05-26,,,2016-09-22,,2018-10-25,2019-04-30,2019-04-30,,,,2020-10-30,2019-07-29,,,,,90,5,5,,412,,,,,,187,187
1140,Pevonedistat-2001,pevonedistat (TAK-924),"A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia",II,Recruitment Complete,Oncology,120,123,0,0,0,0,9,102.50%,72,26,0,PPD,0,,,2015-02-25,,,2016-04-14,,2017-06-21,,2019-09-04,,,,,2019-10-29,,,,,55,5,5,,,,,,,,,805
1141,Pevonedistat-1012,pevonedistat (TAK-924),"A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in
Combination with Azacitidine in Adult East Asian Patients with Acute Myeloid Leukemia (AML)
or Myelodysplastic Syndromes (MDS)",I,Recruitment Complete,Oncology,37,23,0,0,0,0,20,62.16%,9,4,0,PPD,0,,,2016-02-04,,,2016-05-30,,2017-11-20,,2018-04-16,,,,,2018-06-18,,,,,63,5,5,,,,,,,,,147
1142,C31005,sapanisertib,"A Phase 1b/2, Open-Label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and Combination of MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced Clear-Cell Renal Cell Carcinoma That Has Progressed During or After VEGF-Targeted Therapy",II,Reported,Oncology,96,95,147,0,51,37,87,98.96%,55,3,0,PRA,0,,2014-11-04,2015-05-22,,,2016-09-09,,2018-04-10,2018-10-10,2020-03-06,,,,2020-10-13,2020-04-30,,,,,55,5,5,,199,,,,,,183,696
1158,AD-4833/TOMM40_301,AD-4833/TOMM40,"A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects",III,Closed,NS,"3,500","3,494",24235,0,20741,0,3398,99.83%,59,65,0,IQVIA,0,,2012-04-19,2013-02-08,,2013-08-01,2013-08-28,,2015-12-21,,2018-08-07,,,,,2018-09-18,,,,,42,5,5,,295,,,27,,,,960
1159,AD-4833/TOMM40_302,AD-4833/TOMM40,Validation Study to Determine Performance Characteristics and Normative Values for Common Cognitive Instruments used to Detect Dementia and Lesser Cognitive Impairments in the Elderly,III,Closed,NS,675,678,784,0,106,0,0,100.44%,4,0,0,Covance,0,,2012-08-15,2013-06-06,,2013-11-29,2013-11-29,,2014-11-20,,2014-12-18,,,,,2015-03-18,,,,,90,5,5,,295,,,0,,,,28
1160,AD-4833-TOMM40_303,AD-4833/TOMM40,A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the Ad-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impariment Due to Alzheimer Disease,III,Closed,NS,149,40,0,0,0,4,0,26.85%,44,0,0,IQVIA,0,,2013-01-25,2014-03-26,,2015-02-12,2015-02-12,,2017-11-15,,2018-05-09,,,,,2018-09-19,,,,,133,5,5,,425,,,0,,,,175
1166,e0035,soticlestat (TAK-935),Evaluation of [18F]MNI-792 as PET tracer in Healthy Volunteers,I,Closed,NS,11,9,13,0,1,0,3,81.82%,1,0,0,In-House,0,,2014-08-06,2014-09-02,,2014-10-17,2014-10-28,,2015-02-25,,2015-03-02,,,,,2015-03-04,,,,,2,5,5,,27,,,11,,,,5
1176,Leuprorelin-5001,LEUPLIN (leuprorelin acetate),An Observational Retrospective Study to Evaluate the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty,IV,Closed,NonCore,100,108,129,0,20,0,1,108.00%,8,0,0,Hangzhou Tigermed Consulting,0,,2016-08-16,2016-10-10,,,2017-06-24,,2018-09-30,,2018-09-30,,,,,2019-01-30,,,,,122,5,5,,55,,,,,,,0
1212,MLN0002-2003,Entyvio,"A Phase 2, Randomized, Double-Blind, Dose Ranging Study to determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease",II,Reported,GI,80,90,138,0,48,90,23,112.50%,71,5,0,PRA,0,,2014-08-08,2016-10-10,,2017-11-08,2017-12-04,,2019-12-22,,2020-05-26,,,,,2020-05-27,,,,,1,5,5,,794,,,26,,,,156
1215,MLN0002-3026,Entyvio,"A randomized double blind, double dummy multicenter active controlled study to evaluate the efficacy and safety of Vedolizumab IV compared to Adalimumab SC in subjects with Ulcerative Colitis",III,Closed,GI,758,769,1285,0,516,0,243,101.45%,331,0,0,IQVIA,0,,2014-12-12,2015-02-27,,,2015-07-10,,2017-09-27,,2019-01-18,,,,,2019-03-08,,,,,49,5,5,,77,,,,,,,478
1216,MLN0002-3028,Entyvio,An Open Label Phase 3b Study to Assess Mucosal Healing in Patients with Moderatively to Severely Active Crohn's Disease Treated With Vedolizumab,III,Closed,GI,100,80,8,0,49,2,0,80.00%,75,0,0,IQVIA,0,,2014-07-16,2014-12-03,,,2015-04-13,,2016-11-30,,2018-02-21,,,,,2018-04-06,,,,,44,5,5,,140,,,,,,,448
1218,MLN0002SC-3030,Entyvio SC,"A Phase 3b Open-Label Study to Determine the Long-term Safety and Efficacy of
Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn’s Disease",III,Recruitment Complete,GI,746,747,0,0,0,28,387,100.13%,348,0,0,IQVIA,0,,2014-12-12,2015-02-27,,2016-04-15,2016-04-15,,2019-05-14,,2018-05-31,2019-04-15,2019-05-17,2019-07-25,,2018-11-07,2019-06-10,2019-07-30,2019-09-12,,160,5,5,,77,,,0,,,,-348
1219,MLN0002SC-3031,Entyvio SC,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn’s Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy",III,Closed,GI,645,644,1072,0,428,0,169,99.84%,222,0,0,IQVIA,0,,2014-12-11,2015-02-26,,2015-12-14,2016-01-04,,2018-04-25,,2019-05-06,,,,2019-08-21,2019-07-02,,,,2019-10-11,57,5,5,,77,,,21,,,,376
1229,MLN9708_101,Ninlaro,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Safety, Toelrability and PK Study of Multiple Rising Doses of  of MLN9708 for the Treatment of Subjects ith ISN/RPS Class III or IV Lupus Nephritis",I,Terminated,Oncology,40,12,0,0,0,0,0,30.00%,34,0,0,PPD,0,,,2013-12-17,,,2014-07-09,,2017-06-19,2018-01-15,2018-01-15,,,,,2018-03-09,,,,,53,5,5,,,,,,,,210,210
1243,MLN0002SC-3027,Entyvio SC,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, with a Vedolizumab IV
Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as
Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy",III,Closed,GI,400,203,1,0,116,1,0,50.75%,250,0,0,IQVIA,0,,2014-12-12,2015-02-27,,2016-02-19,2016-01-08,,2017-05-31,,2018-05-30,,,,2018-08-21,2018-07-03,,,,2018-11-30,34,5,5,,77,,,-42,,,,364
1253,TAK-831-1001,TAK-831,"A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF ESCALATING SINGLE AND MULTIPLE DOSES OF TAK-831 IN HEALTHY SUBJECTS",I,Closed,NS,120,280,0,0,0,29,0,233.33%,1,0,0,IQVIA,0,,2015-03-11,2015-07-16,,2015-09-23,2015-10-07,,2016-06-01,,2016-06-09,,,,,2016-10-12,,,,,125,5,5,,127,,,14,,,,8
1256,TAK-831-1003,TAK-831,"A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine D-Amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-Dose Oral Administration",I,Closed,NS,22,16,0,0,5,0,0,72.73%,1,0,0,IQVIA,0,,2015-06-30,2015-11-25,,2016-03-21,2016-04-06,,2016-08-04,,2016-08-30,,,,,2016-11-16,,,,,78,5,5,,148,,,16,,,,26
1260,TAK-831-1501,TAK-831,"A Phase II, Randomized, Investigator-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Efficacy, Safety, Tolerability and Pharmacokinetics of Acute Multiple Rising Doses of  Oral TAK-831 in Adult Patients with Friedreich’s Ataxia (FRDA)",II,Closed,NS,65,63,0,0,14,0,0,96.92%,6,0,0,IQVIA,0,,2017-02-20,2017-04-15,,2017-11-01,2017-11-28,,2018-09-27,,2018-12-27,,,,,2019-02-11,,,,,46,5,5,,54,,,27,,,,91
1267,TAK-831-2002,TAK-831,POC SCH,II,Completed,NS,234,307,504,0,198,257,31,131.20%,48,0,0,IQVIA,0,,2017-08-31,2017-10-17,,2018-01-04,2018-02-19,,2020-10-09,,2021-01-12,,,,,2021-02-17,,,,,36,5,5,,47,,,46,,,,95
1272,TAK-831-1006,TAK-831,T2/T3 Food Effect,I,Closed,NS,16,16,58,0,42,0,0,100.00%,1,0,0,Celerion,0,,2018-08-02,2018-10-02,,2018-10-18,2018-11-03,,2018-11-03,,2018-12-22,,,,,2019-01-30,,,,,39,5,5,,61,,,16,,,,49
1273,TAK-831-1004,TAK-831,"An Open-Label, Single-Dose, 2-Period Sequential Design Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of  TAK-831 Formulation T2 in Healthy Subjects",I,Closed,NS,16,15,38,0,23,0,1,93.75%,1,0,0,PRA,0,,2017-01-11,2017-02-20,,2017-03-29,2017-04-25,,2017-05-02,,2017-05-24,,,,,2017-07-24,,,,,61,5,5,,40,,,27,,,,22
1302,SYR-322_104,Nesina (Alogliptin),"A Single Dose PK, PD and Safety Study of 12.5 and 25 mg SYR-322 Administered Orally to Children and Adolescents and  Adults with Type 2 (Non-Insulin Dependent) Diabetes Mellitus",I,Closed,NonCore,48,47,126,0,80,0,1,97.92%,4,0,0,Covance,0,,,2008-11-20,,,2009-11-09,,2013-11-14,,2013-11-22,,,,,2014-03-10,,,,,108,5,5,,,,,,,,,8
1306,SYR-322MET_303,Nesina (Alogliptin),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin and Metformin Fixed Dose Combination, Alogliptin Alone, or Metformin Alone in Subjects with Type 2 Diabetes Mellitus",III,Closed,NonCore,659,651,1266,0,431,0,134,98.79%,71,22,0,Covance,0,,2011-03-29,2011-08-18,,2013-08-27,2013-10-07,,2015-03-31,,2015-10-05,,,,,2016-06-29,,,,,268,5,5,,142,,,41,,,,188
1307,SYR322MET-1003,Nesina (Alogliptin),"An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Comparative Bioavailability and Bioequivalence of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet Vipdomet (Alogliptin FDC with Metformin) in Russian Healthy Subjects.",I,Closed,NonCore,24,24,36,0,8,0,0,100.00%,1,1,0,PPD,0,,2014-10-09,2015-02-11,,2016-03-17,2016-04-08,,2016-04-15,,2016-04-27,,,,,2016-06-15,,,,,49,5,5,,125,,,22,,,,12
1310,TAK-063_102,TAK-063,"A Randomized, Investigator and Subject-Blind, Placebo-Controlled, Single-Dose, 3-Period,
Incomplete Block Cross-Over Study to Evaluate the Effects of Single Oral Administration
of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as
Psychotic-Like Symptoms in Healthy Male Adults",I,Closed,RGH,27,27,58,0,31,0,7,100.00%,1,0,0,Covance,0,,2012-06-25,2013-03-28,,2013-06-27,2013-08-05,,2014-07-21,,2014-08-28,,,,,2015-08-13,,,,,350,5,5,,276,,,39,,,,38
1311,TAK-063_103,TAK-063,"An Open-Label [11C]T-773 Positron Emission Tomography Study to Determine
Phosphodiesterase10A Occupancy by TAK-063 After a Single Oral Dose in Human
Volunteers",I,Closed,RGH,18,13,36,0,21,0,1,72.22%,1,0,0,Covance,0,,2012-10-17,2013-05-14,,2013-08-13,2013-10-09,,2014-02-27,,2014-03-12,,,,,2014-06-12,,,,,92,5,5,,209,,,57,,,,13
1314,TAK-491_305,EDARBI (azilsartan medoxomil),"Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 with Valsartan in Chinese Subjects with Essential Hypertension",III,Closed,NonCore,600,582,0,0,95,12,0,97.00%,30,0,0,IQVIA,0,,2011-02-16,2011-04-28,,2015-08-27,2015-09-21,,2017-08-31,,2017-10-27,,,,,2017-12-08,,,,,42,5,5,,71,,,25,,,,57
1316,TAK-491_112,EDARBI (azilsartan medoxomil),"A Randomized, Open-Label and Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Phase 1 Study of the Pharmacokinetics of TAK-491 40 mg and 80 mg in
Healthy Chinese Subjects",I,Closed,NonCore,64,53,0,0,147,0,0,82.81%,1,0,0,IQVIA,0,,2011-03-18,2011-04-26,,2015-11-17,2015-11-20,,2017-02-22,,2017-03-19,,,,,2017-05-03,,,,,45,5,5,,39,,,3,,,,25
1319,TAK-653-1001,TAK-653,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-653 in Healthy Subjects",I,Closed,NS,72,88,0,0,0,0,1,122.22%,1,0,0,PPD,0,,2015-05-01,2015-06-24,,2015-08-26,2015-09-14,,2017-08-17,,2017-09-23,,,,,2017-10-20,,,,,27,5,5,,54,,,19,,,,37
1345,TAK-063-2002,TAK-063,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-week Study to Evaluate the Efficacy and Safety of  Three Doses (5 mg,10 mg, 20 mg) of Oral TAK-063 in Patients (Acute SZC)",II,Closed,RGH,160,115,0,0,42,0,0,71.88%,16,0,0,IQVIA,0,,2015-01-13,2015-03-26,,2015-07-01,2015-07-07,,2016-05-31,,2016-07-27,,,,,2016-09-09,,,,,44,5,5,,72,,,6,,,,57
1361,TAK-390MR_207,"DEXILANT (dexlansoprazole, MR)","A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral
Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive
Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn, in
Adolescent Subjects Aged 12 to 17 Years",II,Closed,NonCore,63,0,0,0,0,0,0,0.00%,58,2,0,IQVIA,0,,2011-06-06,2012-02-09,,2012-07-17,2012-07-18,,2014-03-04,,2014-11-10,,,,,2014-12-18,,,,,38,5,5,,248,,,1,,,,251
1363,TAK-438_114,vonoprazan,"An Open-Label, Single-center, Parallel, Phase 1 Study to Determine the Pharmacokinetics of Single- and Multiple- Oral Doses of TAK-438 10 mg and 20 mg in Healthy Adult Chinese Subjects",I,Closed,GI,36,33,104,0,71,0,0,91.67%,1,0,0,IQVIA,0,,2012-08-01,2012-08-01,,,2017-04-25,,2017-08-01,,2017-08-18,,,,,2017-10-04,,,,,47,5,5,,0,,,,,,,17
1364,TAK-438_303,vonoprazan,"Randomized, Double-Blind, Double-Dummy, TAK-438 20 mg, QD vs, Lansoprazole 30 mg QD,  Erosive Esophagitis",III,Closed,GI,480,288,0,0,91,4,0,60.00%,63,0,0,IQVIA,0,,2012-05-09,2012-08-08,,2015-03-09,2015-03-30,,2017-06-13,,2017-07-27,,,,,2017-09-01,,,,,36,5,5,,91,,,21,,,,44
1365,TAK-438_305,vonoprazan,"A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis",III,All Activities Closed,GI,693,630,1,0,181,5,0,90.91%,72,0,0,IQVIA,0,,2012-08-22,2012-08-29,,2015-04-01,2015-04-08,,2018-07-03,,2018-12-31,,,,,2019-11-18,,,,,322,5,5,,7,,,7,,,,181
1373,TAK-063_104,TAK-063,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK-063 in Subjects with Stable Schizophrenia and Healthy Japanese Subjects",I,Closed,RGH,90,77,162,0,85,0,4,85.56%,1,0,0,Covance,0,,2013-02-06,2013-03-26,,2013-06-21,2013-07-19,,2014-06-10,,2014-06-23,,,,,2014-08-20,,,,,58,5,5,,48,,,28,,,,13
1378,TAK-390MR_104,"DEXILANT (dexlansoprazole, MR)","Phase 1, Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Effect of TAK-390MR 60 mg and Esomeprazole 40 mg on Bone Metabolism in Healthy Postmenopausal Female Subjects",I,Closed,NonCore,240,247,1488,0,1241,0,38,102.92%,11,0,0,IQVIA,0,,2009-04-16,2010-06-30,,2010-11-04,2011-01-24,,2013-01-18,,2014-01-19,,,,,2014-12-10,,,,,325,5,5,,440,,,81,,,,366
1394,TAK-935_101,soticlestat (TAK-935),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects",I,Closed,NS,48,48,177,0,129,0,0,100.00%,1,0,0,PPD,0,,2014-03-17,2014-04-24,,2014-07-09,2014-07-31,,2015-07-10,,2015-07-16,,,,,2015-09-10,,,,,56,5,5,,38,,,22,,,,6
1395,TAK-935_1002,soticlestat (TAK-935),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and
Pharmacokinetic Study of Escalating Multiple Doses of TAK-935 in Healthy Subjects",I,Closed,NS,40,40,176,0,136,0,16,100.00%,1,0,0,PPD,0,,2015-03-30,2015-07-07,,2015-09-02,2015-09-27,,2016-03-20,,2016-04-19,,,,,2016-06-17,,,,,59,5,5,,99,,,25,,,,30
1397,TAK-935_1003,soticlestat (TAK-935),"An Open-Label, Positron Emission Tomography, Phase 1 Study with [18F]MNI-792 to Determine Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 After Single-Dose Oral Administration in Healthy Subjects",I,Closed,NS,11,11,26,0,15,0,0,100.00%,1,0,0,PPD,0,,,2015-05-14,,2015-07-01,2015-07-15,,2015-11-20,,2016-01-06,,,,,2016-03-04,,,,,58,5,5,,,,,14,,,,47
1400,TMX-67_204,ULORIC (febuxostat),"A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects with Early Gout",II,Closed,NonCore,300,0,0,0,0,0,0,0.00%,85,0,0,Covance,0,,2009-05-08,2009-08-19,,,2010-03-25,,2011-08-25,,2013-09-03,,,,,2013-12-09,,,,,97,5,5,,103,,,,,,,740
1401,TMX-67_206,ULORIC (febuxostat),"A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension",II,Closed,NonCore,120,0,0,0,0,0,0,0.00%,40,0,0,Covance,0,,2011-05-24,2011-09-13,,2012-01-14,2012-02-04,,2014-06-12,,2014-08-04,,,,,2014-10-14,,,,,71,5,5,,112,,,21,,,,53
1402,TMX-67_301,ULORIC (febuxostat),"A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities",III,Closed,NonCore,"7,500","6,193",0,0,0,0,2737,82.57%,450,0,0,PPD,0,,2009-04-09,2009-08-24,,2010-04-23,2010-04-30,,2016-07-25,,2017-05-15,,,,,2017-08-08,,,,,85,5,5,,137,,,7,,,,294
1403,Vedolizumab-4001,Entyvio,Conduct a milk-only lactation study in lactating women receiving MLN0002 therapeutically to assess concentrations of vedolizumab in breast milk using a validated assay,IV,Closed,GI,12,11,0,0,0,0,1,91.67%,8,0,0,PPD,0,,2014-08-18,2015-03-31,,2017-11-29,2017-12-12,,2018-12-27,,2019-02-22,,,,,2019-04-05,,,,,42,5,5,,225,,,13,,,,57
1410,TAK-020-1001,TAK-020,"Ph 1 Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Single, MRD to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-020 in Healthy Volunteers",I,Closed,NonCore,128,114,0,0,377,120,0,89.06%,1,0,0,IQVIA,0,,2014-11-04,2014-12-19,,2015-03-09,2015-04-06,,2017-04-17,,2017-05-04,,,,,2017-07-25,,,,,82,5,5,,45,,,28,,,,17
1411,TAK-020-1002,TAK-020,"A Randomized, Open Label Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of a Single Dose of Various Test Solid Formulations of TAK-020 Compared With a Single Dose of Reference Oral Solution and to Evaluate the Food Effect and Potentially the Dose Proportionality of the Optimal Solid Dose Formulation",I,Closed,NonCore,25,23,0,0,62,25,0,92.00%,1,0,0,IQVIA,0,,2015-05-20,2015-12-11,,2016-04-28,2016-05-25,,2016-07-26,,2016-08-19,,,,,2016-11-07,,,,,80,5,5,,205,,,27,,,,24
1472,0624-209,CINRYZE,"A PHASE 3, OPEN-LABEL, SINGLE-PERIOD STUDY TO EVALUATE THE SAFETY AND TREATMENT EFFECT OF INTRAVENOUS ADMINISTRATION OF CINRYZE™ (C1 INHIBITOR [HUMAN]) FOR THE PREVENTION OF ANGIOEDEMA ATTACKS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA (HAE)",III,Completed,NonCore,8,8,8,0,0,8,0,100.00%,10,0,ViroPharma,Parexel,0,,2015-12-10,2016-02-17,,2016-09-12,2016-09-13,,2017-03-07,,2017-06-23,,,,,2017-07-27,,,,,34,5,5,,69,,,1,,,,108
1527,60402,Advate (Antihemophilic Factor (Recombinant)),"ADVATE Randomized Surgery: Ph 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare Efficacy & Safety of CI vs Intermittent BI in Subjects with Severe/Moderately Severe Hemophilia A in Subjects Undergoing Major Orthopedic Surgery",IV,Completed,RGH,60,61,86,3,15,0,12,101.67%,30,0,Baxalta,IQVIA,0,11/24/2016,,2004-11-18,,2006-05-29,2006-06-13,,2015-08-24,,2016-05-09,,,,,2016-03-11,,,,,-59,5,5,,,,,15,,,,259
1546,71301,Vonvendi (von Willebrand factor (recombinant)),"SHP677 Vonvendi (BAX111) rVWF LT Prophy: A Prospective, Phase 3, Open Label, International Multicenter Study on Efficacy and Safety of Prophylaxis with  rVWF in Severe vonWillebrand Disease",III,Completed,RGH,22,23,0,0,6,0,0,104.55%,32,0,0,IQVIA,0,,,2014-02-19,,2017-10-25,2017-12-22,,2019-06-17,,2020-08-25,,,,,2020-10-22,,,,,58,5,5,,,,,58,,,,435
1553,91301,FEIBA,FEIBA NF Global Outcome Study,IV,Completed,NonCore,55,53,53,0,0,0,42,96.36%,40,0,0,Synteract,0,,,2013-09-30,,,2014-09-03,,2017-12-19,,2020-02-28,,,,,2020-08-31,,,,,185,5,5,,,,,,,,,801
1591,241302,Obizur (antihemophilic factor [recombinant] porcine sequence),OBIZUR US PMR: Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A,IV,Completed,RGH,40,53,0,0,0,0,0,132.50%,40,0,0,IQVIA,0,,2013-10-31,2015-03-11,,2015-12-30,2015-12-30,,2018-10-19,,2019-06-07,,,,,2021-04-16,,,,,679,5,5,,496,,,0,,,,231
1630,471101,GLASSIA,"A Phase 3/4 Study to Evaluate the Safety, Immunogenicity,
and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels
in Epithelial Lining Fluid Following GLASSIA Therapy in
A1PI-Deficient Subjects",IV,Completed,NonCore,36,36,0,0,25,0,0,100.00%,20,0,0,IQVIA,0,,2015-10-21,2016-01-19,,2016-03-08,2016-04-21,,2020-02-05,,2020-07-29,,,,,2020-11-09,,,,,103,5,5,,90,,,44,,,,175
1690,Cabozantinib-2001,cabozantinib,Cabozantinib-2001 Japan Ph 2 study (RCC 2nd Line),II,Enrollment Complete,Oncology,35,35,46,0,11,0,0,100.00%,19,0,0,MEDISCIENCE PLANNING INC,0,,,2017-08-24,,2017-11-16,2017-12-27,,2018-07-03,2019-04-30,2018-10-23,,,,2020-08-25,2018-12-18,,,,2020-11-19,56,5,5,,,,,41,,,301,112
1692,Cabozantinib-2003,cabozantinib,Cabozantinib-2003 Japan Ph2 study (HCC 2nd Line),II,Enrollment Complete,Oncology,32,34,39,0,8,0,0,106.25%,18,0,0,Takeda PRA Development Center,0,,,2018-04-26,,2018-08-12,2018-08-27,,2019-01-29,2019-07-28,2019-07-23,,,,2020-12-24,2019-09-19,,,,2021-03-24,58,5,5,,,,,15,,,180,175
1693,Darvadstrocel-3002,Alofisel,"A Phase 3, Multicenter, Open-Label, Uncontrolled Study to Evaluate the Efficacy and
Safety of Cx601 in the Treatment of Complex Perianal Fistulas in Adult Patients with
Crohn's Disease",III,Enrollment Complete,GI,20,22,0,0,4,0,0,110.00%,7,0,0,MEDISCIENCE PLANNING INC,0,,2017-09-26,2018-04-20,,2019-03-06,2019-03-28,,2020-02-04,,2020-07-20,2021-02-01,,,,2020-11-11,2021-03-26,,,,114,5,5,,206,,,22,,,,167
1698,C16028,Ninlaro,"C16028 A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myelom",II,Closed,Oncology,30,34,43,0,9,0,6,113.33%,20,0,0,EPS,0,,,2016-08-23,,2016-11-04,2016-11-22,,2017-08-04,2019-08-04,2018-08-03,,,,2019-08-04,2018-10-02,,,,2019-11-01,60,5,5,,,,,18,,,730,364
1699,TB-MC010034,Ninlaro,MLN9708/ONC-001 MLN9708 TB-MC010034 (ONC-001) - P1/1b Relapased or Refractory Multiple Myeloma Mono+Combo (capsule),I,Closed,Oncology,1,0,0,0,0,0,0,0.00%,5,0,0,Takeda PRA Development Center,0,,,2012-01-16,,2012-05-23,2012-06-06,,2013-10-02,2015-03-21,2019-02-15,,,,,2019-05-15,,,,,89,5,5,,,,,14,,,535,1962
1700,Niraparib-1001,Niraparib,JPN Ph1 study (Ovarian) (Niraparib),I,Closed,Oncology,9,9,11,0,2,0,8,100.00%,1,0,0,Takeda PRA Development Center,0,,,2018-01-23,,2018-04-23,2018-04-27,,2018-10-23,2018-12-29,2018-12-03,,,,2020-02-10,2019-05-20,,,,2020-06-18,168,5,5,,,,,4,,,67,41
1702,SYR-472-3003,Zafatek (Trelagliptin),SYR-472/CCT-201 Phase 3 - Pivotal/Long-term Safety Study,III,Closed,NonCore,107,107,267,0,160,0,25,100.00%,51,0,0,A2 Healthcare,0,,2015-02-05,2015-04-01,,2015-08-07,2015-09-14,,2017-04-11,,2018-04-24,,,,,2018-06-18,,,,,55,5,5,,55,,,38,,,,378
1703,Vonoprazan-3001,vonoprazan,3001 P3 NERD (TAK-438),III,Closed,GI,484,484,0,0,0,0,0,100.00%,45,0,0,EPS,0,,2016-01-19,2016-08-31,,2016-11-15,2016-11-25,,2018-01-29,,2018-02-26,,,,,2018-05-29,,,,,92,5,5,,225,,,10,,,,28
1704,TAK-438ASA-1001,vonoprazan ASA,1001 BE Study (TAK-438 ASA) (vonoprazan ASA (TAK-438 ASA)),I,Closed,GI,552,548,0,0,0,0,0,99.28%,1,0,0,MEDISCIENCE PLANNING INC,0,,2017-10-19,2017-12-29,,2018-03-08,2018-04-02,,2018-10-10,,2018-10-12,,,,,2018-12-27,,,,,76,5,5,,71,,,25,,,,2
1705,TAK-536/OCT-101,Azilva (azilsartan),TAK-536/OCT-101 Phase 3 - Long-term Safety Study in 6 to 16 y/o HTN patients,III,Closed,NonCore,30,27,35,0,8,0,4,90.00%,32,0,0,MEDISCIENCE PLANNING INC,0,,,2016-03-22,,2016-08-02,2016-09-09,,2018-05-29,,2019-06-04,,,,,2019-07-23,,,,,49,5,5,,,,,38,,,,371
1706,TAK-831-1002,TAK-831,Asia SRD/MRD (TAK-831),I,Closed,NS,40,40,0,0,0,0,0,100.00%,1,0,0,Takeda PRA Development Center,0,,2018-06-19,2018-09-05,,2018-10-09,2018-10-19,,2019-05-22,,2019-06-19,,,,,2019-07-23,,,,,34,5,5,,78,,,10,,,,28
1707,TAK-906-1004,TAK-906,1.1 TAK-906-1004 Japan SAD/MAD study,I,Closed,GI,24,24,0,0,0,0,0,100.00%,1,0,0,MEDISCIENCE PLANNING INC,0,,2017-02-22,2017-05-26,,2017-08-07,2017-08-25,,2017-09-14,,2017-10-07,,,,,2017-12-15,,,,,69,5,5,,93,,,18,,,,23
1709,TAK-925-1001,TAK-925,1001 Ph1 SRD POM study (TAK-925),I,Closed,NS,101,101,0,0,0,0,0,100.00%,1,0,0,MEDISCIENCE PLANNING INC,0,,2017-07-12,2017-09-11,,2017-11-11,2017-11-20,,2018-08-31,,2018-09-04,,,,,2018-10-12,,,,,38,5,5,,61,,,9,,,,4
1711,TAK-438ODT-1001,vonoprazan OD,"An Open-Label, Crossover Phase 1 Study to Evaluate the Bioequivalence of TAK-438 OD (Orally Disintegrating) Tablet When Administered without Water (Study 1) or with Water (Study 2) and TAK-438 tablet in Healthy Adult Male Subjects",I,Closed,GI,96,96,0,0,0,0,0,100.00%,1,0,0,Takeda PRA Development Center,0,,2018-09-20,2018-12-12,,2019-01-30,2019-02-14,,2019-03-02,,2019-03-12,,,,,2019-06-17,,,,,97,5,5,,83,,,15,,,,10
1712,MLN0002/CCT-101,Entyvio,CCT-101 P3 Comparator study UC (Vedolizumab),III,Closed,GI,278,292,344,0,52,0,49,105.04%,100,0,0,MEDISCIENCE PLANNING INC,0,,,2013-11-11,,2014-02-04,2014-02-13,,2015-11-10,,2016-12-03,,,,2018-02-27,2017-02-20,,,,2018-08-16,79,5,5,,,,,9,,,,389
1713,MLN0002/CCT-001,Entyvio,CCT-001 P3 Comparator study CD (Vedolizumab),III,Closed,GI,110,157,194,0,37,0,25,142.73%,60,0,0,MEDISCIENCE PLANNING INC,0,,,2013-11-11,,2014-01-28,2014-02-10,,2016-09-29,,2017-11-16,,,,2019-01-25,2018-02-06,,,,2019-07-10,82,5,5,,,,,13,,,,413
1714,Azilsartan-1005,Azilva (azilsartan),1005 Definitive FE with Ped (TAK-536) (Azilva (azilsartan)),I,Closed,NonCore,23,23,0,0,0,0,0,100.00%,1,0,0,MEDISCIENCE PLANNING INC,0,,2017-10-03,2017-12-05,,2018-02-14,2018-02-28,,2018-03-06,,2018-03-11,,,,,2018-04-06,,,,,26,5,5,,63,,,14,,,,5
1715,Niraparib-2002,Niraparib,JPN Ph2 study (Ovarian) (Niraparib),II,"Active, Not Recruiting",Oncology,16,20,35,0,15,0,8,125.00%,30,0,0,MEDISCIENCE PLANNING INC,0,,,2018-11-14,,2018-12-26,2019-01-21,,2019-04-01,2020-06-09,2019-07-01,,,,,2019-08-23,,,,,53,5,5,,,,,26,,,435,91
1716,Niraparib-2001,Niraparib,JPN Ph2 2nd line maintenance study (Ovarian) (Niraparib),II,Enrollment Complete,Oncology,15,19,21,0,2,0,9,126.67%,30,0,0,MEDISCIENCE PLANNING INC,0,,,2018-11-14,,2018-12-28,2019-01-08,,2019-02-12,2020-11-03,2019-03-17,,,,,2019-05-20,,,,,64,5,5,,,,,11,,,630,33
1718,TAK-925-1003,TAK-925,1003 Ph1 MRD POM study (TAK-925),I,Closed,NS,54,57,0,0,0,0,0,105.56%,3,0,0,Takeda PRA Development Center,0,,2018-08-29,2018-10-05,,2018-11-21,2018-12-15,,2019-10-11,,2019-10-25,,,,,2019-11-21,,,,,27,5,5,,37,,,24,,,,14
1723,TAK-123-1001,Ammonul (sodium phenylacetate and sodium benzoate),TAK-123 Ph-1 Japan study,I,Closed,NonCore,10,10,0,0,0,0,0,100.00%,1,0,0,PRA,0,,2019-05-22,2019-08-21,,2019-11-13,2019-11-29,,2019-11-29,,2019-12-18,,,,,2020-01-10,,,,,23,5,5,,91,,,16,,,,19
1785,DX-2930-03,Takhzyro (Lanadelumab),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE).",III,Completed,RGH,120,125,0,0,6,125,11,104.17%,60,0,Dyax,IQVIA,1-Aug-17,4/13/2017,2015-08-05,2015-09-14,,,2016-03-03,,2016-09-06,,2017-04-13,,,,,2017-05-10,,,,,27,5,5,-617,40,,,,,,,219
1786,DX-2930-04,Takhzyro (Lanadelumab),"HELP Study Extension: An Open-Label Study to Evaluate the
Long-Term Safety and Efficacy of DX-2930 for Prevention Against
Acute Attacks of Hereditary Angioedema (HAE).",III,Completed,RGH,250,0,0,0,0,0,0,0,60,0,Dyax,"Red Maple Trials, Rho, Triumpharma",26-Feb-20,,2015-08-05,2015-12-14,,,2016-05-26,,2017-03-30,,2019-10-31,,,,,2019-12-17,,,,,47,5,5,,131,,,,,,,945
1813,HGT-HIT-094,idursulfase IT (TAK-609),"A Controlled, Randomized, Two-Arm, Open-label, Assessor-blinded, Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Intravenous Elaprase® in Pediatric Patients with Hunter Syndrome and Early Cognitive Impairment",III,Completed,RGH,0,58,0,0,0,0,2,0,12,0,Shire HGT,PPD,0,1/9/2017,2012-09-11,2013-04-04,,2014-04-03,2014-04-03,,2016-09-30,,2017-09-28,,,,,2017-12-04,,,,,67,5,5,-1581,205,,,0,,,,363
1817,HGT-MLD-070,arylsulfatase A (TAK-611),A Phase I/II Multicenter Open-label Dose Escalation Study of HGT-1110 Administered Intrathecally (IT) in Children with Metachromatic Leukodystrophy,II,Completed,RGH,24,24,34,0,11,24,2,100.00%,6,0,0,ICON / MAPI / Paradigm,0,,2010-06-24,2011-01-24,,2012-02-17,2012-08-01,,2016-04-07,,2017-02-20,,,,,2017-03-13,,,,,21,5,5,,214,,,166,,,,319
1859,PAR-C10-008,Natpara (parathyroid hormone),"A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults with Hypoparathyroidism – A Clinical Extension Study (RACE)",III,Completed,RGH,40,53,0,0,0,0,13,132.50%,12,0,"(NPS) National Pharmaceutical Services, Inc",Medpace,0,7/2/2019,2010-11-22,2010-12-30,,2011-03-30,2011-04-06,,2012-01-30,,2018-01-30,,,,,2018-07-03,,,,,154,5,5,-3144,38,,,7,,,,2192
1882,ROPP-2008-01,TAK-607 (mecasermin rinfabate),"Determination of the rhIGF-I/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-I Levels within Physiological Levels in Premature Infants, to prevent Retinopathy of Prematurity A Phase II, Randomized Controlled, Assessor-blind, Dose-Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study.",II,Completed,RGH,120,121,0,0,0,121,28,100.83%,25,0,0,PPD,0,,2014-06-08,2014-08-27,,2015-03-19,2015-03-26,,2015-12-31,,2016-04-27,,,,,2016-06-08,,,,,42,5,5,,80,,,7,,,,118
1887,SHP465-112,Mydayis (Mixed Amphetamine Salts),"A Phase 1, open-label study of the pharmacokinetics of d- and l-amphetamine after  multiple doses of SHP465 6.25 mg, 12.5 mg, and 25 mg administered to children aged 4 through 5 years with Attention-Deficit Hyperactivity Disorder (ADHD)",I,Completed,NS,0,24,0,0,0,0,2,0,10,0,0,PPD,15-Feb-19,1/31/2019,,2017-09-21,,,2018-03-13,,2018-09-07,,2018-10-05,,,,,2018-11-16,,,,,42,5,5,,,,,,,,,28
1891,SHP465-308,Mydayis (Mixed Amphetamine Salts),"A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed with Attention-deficit/Hyperactivity Disorder",III,Study Terminated,NS,0,282,0,0,0,0,172,0,45,0,0,Endpoint,2-Feb-19,5/22/2019,,2017-09-11,,,2018-01-22,,2018-05-09,,2019-01-18,,,,,2019-02-15,,,,,28,5,5,,,,,,,,,254
1892,SHP465-309,Mydayis (Mixed Amphetamine Salts),"A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled,  Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years with Attention-Deficit Hyperactivity Disorder (ADHD)",III,Completed,NS,0,89,0,0,0,0,6,0,45,0,0,PPD,12-Dec-18,12/14/2018,,2017-09-07,,,2017-12-26,,2018-05-02,,2018-06-08,,,,,2018-08-21,,,,,74,5,5,,,,,,,,,37
1925,SHP615-301,Buccolam (Midazolam),"A Multi-center, Open-label, Single-dose, Phase 3 Study of SHP615 Buccally Administered to Pediatric Subjects (aged 3 months to =18 years) with Status Epilepticus (Convulsive)",III,Completed,NS,25,23,0,0,57,0,0,92.00%,25,0,ViroPharma,IQVIA,18-Feb-20,1/9/2020,2016-08-25,2017-01-23,,2017-10-23,2017-11-24,,2019-07-25,,2019-08-02,,,,,2019-09-19,,,,,48,5,5,-1232,151,,,32,,,,8
1926,SHP615-302,Buccolam (Midazolam),"An Open-label, Single-dose, Phase 3 Study of SHP615 Buccally Administered to Pediatric Subjects (aged 6 months to =18 years) with Status Epilepticus (Convulsive) in Community Setting: Extension to Study SHP615-301 in the hospital or emergency room",III,Completed,NS,6,3,0,0,9,1,0,50.00%,25,0,ViroPharma,IQVIA,0,,2016-09-02,2017-03-10,,2018-05-24,2018-05-25,,2020-01-10,,2019-08-31,2019-11-22,,,2020-01-17,2019-09-19,2019-12-20,,,2020-10-30,19,5,5,,189,,,1,,,,-132
1935,SHP616-300,CINRYZE,"A Ph3, rand, db, pcb controlled, 2-period, partial x-over study to evaluate the safety and efficacy of sc admin of 2000U of C1 esterase inhibitor [human] liquid for injection for the prevention of angioedema attacks in adolescents and adults w HAE",III,Completed,NonCore,0,75,0,0,0,0,17,0,40,0,0,PPD,0,,2014-09-08,2015-05-28,,2015-12-17,2016-01-08,,2016-12-05,,2017-07-24,,,,,2017-08-23,,,,,30,5,5,,262,,,22,,,,231
1957,SHP620-303,maribavir (TAK-620),"A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of SHP620 Compared to Standard of Care for the Treatment of Cytomegalovirus (CMV) Infections that are Resistant or Refractory to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir in Transplant Recipients",III,Reported,RGH,351,349,428,4,79,352,74,99.43%,100,4,0,PPD,0,,2015-12-15,2016-04-28,,2016-12-22,2016-12-29,,2020-03-26,,2020-08-17,,,,,2020-11-13,,,,,88,5,5,,135,,,7,,,,144
1960,SHP621-101,budesonide (TAK-721),"A Phase 1, Open-label, Randomized, Two-Sequence, Five-Period, Crossover Study Comparing the Pharmacoinetics of Four Budesonde Oral Suspension Formulations (BOS) and Entocort EC in Healthy Adults",I,Completed,GI,22,0,0,0,0,0,0,0.00%,1,0,0,0,0,,2017-03-13,2017-05-22,,2017-11-08,2017-11-08,,2017-11-08,,2017-11-26,,,,,2018-01-22,,,,,57,5,5,,70,,,0,,,,18
1961,SHP621-102,budesonide (TAK-721),An Open-Label Taste Assessment of Oral Viscous Budesonide in Healthy Patients,I,Completed,GI,16,7,7,0,0,7,0,43.75%,1,0,0,0,0,,2017-09-11,2017-10-25,,2017-12-22,2017-12-22,,2017-12-22,,2017-12-29,,,,,2018-03-08,,,,,69,5,5,,44,,,0,,,,7
1962,SHP621-301,budesonide (TAK-721),"Oral Budesonide Suspension (OBS) in Adolescents and Adult subjects with Eosinophilic Esophagitis: DB, Placebo-Controlled, RW",III,Completed,GI,0,323,0,0,0,0,26,0,60,0,0,PPD,19-Apr-19,7/31/2019,2015-07-27,2015-08-31,,2015-11-10,2015-12-07,,2018-10-08,,2019-02-15,,,,,2019-03-15,,,,,28,5,5,-1465,35,,,27,,,,130
1963,SHP621-302,budesonide (TAK-721),"Oral Budesonide Suspension (OBS) in Adolescents and Adult subjects with Eosinophilic Esophagitis: DB, Maintenance",III,Completed,GI,200,219,231,0,12,219,45,109.50%,60,0,0,Endpoint,0,,2015-11-12,2015-12-03,,2016-04-01,2016-04-29,,2019-02-15,,2019-11-12,,,,,2019-12-12,,,,,30,5,5,,21,,,28,,,,270
1996,SHP633-301,Gattex (teduglutide),"An Open-label, 24-Week Safety and Pharmacodynamic Study of Teduglutide in Infant Subjects Aged 4 Months up to 12 Months, with Short Bowel Syndrome who are Dependent on Parenteral Support",III,Completed,GI,10,10,13,0,3,10,3,100.00%,8,0,0,IQVIA,0,,2015-06-04,2017-10-10,,2018-09-18,2018-09-18,,2020-03-02,,2020-09-18,,,,,2020-10-14,,,,,26,5,5,,859,,,0,,,,200
1997,SHP633-302,Gattex (teduglutide),"A 24-week Safety, Efficacy, Pharmacodynamic, and Pharmacokinetic Study of Teduglutide in Japanese Pediatric Subjects, Aged 4 Months through 15 Years, with Short Bowel Syndrome who are Dependent on Parenteral Support",III,Completed,GI,10,10,0,0,0,0,0,100.00%,6,0,0,IQVIA,0,,2015-04-07,2015-12-18,,2017-01-13,2017-02-01,,2019-07-03,,2020-01-21,,,,,2020-03-04,,,,,43,5,5,,255,,,19,,,,202
1998,SHP633-303,Gattex (teduglutide),"A retrospective and prospective, open label, long-term safety and efficacy study of teduglutide in pediatric patients with short bowel syndrome who participated in TED-C13-003",III,Completed,GI,39,29,0,0,0,0,9,74.36%,12,0,0,IQVIA,0,,2015-12-08,2016-05-11,,2016-11-30,2016-12-09,,2017-08-08,,2020-07-14,,,,,2020-10-09,,,,,87,5,5,,155,,,9,,,,1071
1999,SHP633-304,Gattex (teduglutide),"A prospective, open label, long-term safety and efficacy study of teduglutide in pediatric patients with short bowel syndrome who completed TED-C14-006",III,Completed,GI,57,61,0,0,0,0,9,107.02%,28,0,0,TBD,0,,2015-12-08,2016-04-08,,2017-01-09,2017-01-09,,2020-07-15,,2020-11-05,,,,,2021-01-25,,,,,81,5,5,,122,,,0,,,,113
2001,SHP633-306,Gattex (teduglutide),"A 24-Week Safety, Efficacy, Pharmacokinetic Study of Teduglutide in Japanese Subjects with Short Bowel Syndrome who are Dependent on Parenteral Support",III,Completed,GI,5,7,0,0,3,0,0,140.00%,5,0,0,IQVIA,0,,2017-09-21,2018-01-23,,2018-05-28,2018-07-31,,2019-02-25,,2019-08-06,,,,,2019-09-13,,,,,38,5,5,,124,,,64,,,,162
2004,SHP634-101,Natpara (parathyroid hormone),"An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of QD versus BID Dose Regimens of recombinant parathyroid hormone (rhPTH(1-84)) Administered Subcutaneously to Subjects with Hypoparathyroidism",I,Completed,RGH,34,34,0,0,0,0,1,100.00%,30,0,0,PPD,0,,2015-10-19,2015-11-24,,2017-02-15,2017-03-11,,2019-02-28,,2019-03-08,,,,,2020-02-17,,,,,346,5,5,,36,,,24,,,,8
2005,SHP634-102,Natpara (parathyroid hormone),"A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneiously in Japanese and Matched Caucasian Healthy Adult Subjects",I,Completed,RGH,24,24,44,0,0,24,0,100.00%,1,0,0,Parexel,0,6/26/2017,2016-06-27,2017-02-07,,2017-04-19,2017-05-16,,2017-05-22,,2017-06-26,,,,,2017-08-22,,,,,57,5,5,-364,225,,,27,,,,35
2006,SHP634-103,Natpara (parathyroid hormone),"A Randomized, Open-label, Single-dose, Two-treatment, Two-period Crossover Study to Determine the Bioequivalence of recombinant human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneiously with the Haselmeier and Scandinavian Health Ltd (SHL) Injection Pens in Healthy Volunteers",I,Completed,RGH,58,58,0,0,0,58,0,100.00%,1,0,0,"Clinical Pharmacology of Miami, INC",0,11/10/2017,2017-07-12,2017-08-03,,2017-10-03,2017-10-17,,2017-10-30,,2017-11-03,,,,,2018-03-09,,,,,126,5,5,-121,22,,,14,,,,4
2013,SHP634-402,Natpara (parathyroid hormone),EXTENDED USE OF rhPTH(1-84) [NATPARA] IN HYPOPARATHYROIDISM: A PHASE 4 TRIAL,IV,Reported,RGH,50,36,0,0,0,0,36,72.00%,1,0,0,PPD,0,,2016-04-18,2016-05-27,,2016-10-26,2016-12-09,,2017-06-30,,2019-12-20,,,,,2020-12-04,,,,,350,5,5,,39,,,44,,,,903
2018,SHP639-101,TAK-639,"A Randomized, Double-masked, Placebo-controlle Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Signle Daily and Multiple Daily Ascending Doses of SHP639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-angle Glaucoma (POAG)",I,Completed,NonCore,0,63,0,0,0,0,1,0,7,0,0,PPD,30-May-18,5/30/2018,2016-08-24,2016-12-20,,2017-05-18,2017-05-24,,2018-03-07,,2018-05-30,,,,,2018-11-13,,,,,167,5,5,-644,118,,,6,,,,84
2022,SHP640-303,TAK-640 (dexamethasone),"A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis",III,Completed,NonCore,721,753,1087,0,334,753,57,104.44%,203,0,0,IQVIA,20-Oct-18,10/1/2018,2016-08-01,2016-09-02,,2017-03-06,2017-03-31,,2017-12-17,,2018-10-03,,,,,2018-11-15,,,,,43,5,5,-791,32,,,25,,,,290
2026,SHP643-101,Takhzyro (Lanadelumab),Phase 1 Japanese Bridging Study,I,Completed,RGH,32,32,75,0,0,0,0,100.00%,1,0,0,PPD,0,10/23/2018,,2017-11-28,,,2018-01-31,,2018-02-07,,2018-05-30,,,,,2018-07-30,,,,,61,5,5,,,,,,,,,112
2027,SHP643-102,Takhzyro (Lanadelumab),Pharmacokinetic Comparability of Lanadelumab Using Pre-Filled Syringe or an Auto Injector in Healthy Subjects,I,Completed,RGH,190,190,0,0,0,0,17,100.00%,1,1,0,PPD,0,,,2019-02-04,,,2019-05-14,,2019-07-25,,2019-11-13,,,,,2020-01-03,,,,,51,5,5,,,,,,,,,111
2038,SHP647-301,SHP647,SHP647-301 UC Induction #1,III,Completed,GI,825,380,0,0,0,0,34,46.06%,167,15,0,PPD,0,,,2017-07-18,,2017-11-09,2018-02-09,,2020-04-22,,2020-07-22,,,,,2020-12-02,,,,,133,5,5,,,,,92,,,,91
2039,SHP647-302,SHP647,SHP647-302 UC Induction #2,III,Completed,GI,825,279,0,0,0,0,21,33.82%,168,20,0,PPD,0,,,2017-07-14,,2017-10-31,2017-12-05,,2020-04-21,,2020-07-15,,,,,2020-11-09,,,,,117,5,5,,,,,35,,,,85
2042,SHP647-305,SHP647,SHP647-305 CD Induction #1,III,Completed,GI,"1,032",30,0,0,0,0,2,2.91%,420,5,0,PPD,0,,,2017-12-21,,2018-06-25,2018-08-29,,2020-03-25,,2020-07-07,,,,,2020-11-25,,,,,141,5,5,,,,,65,,,,104
2043,SHP647-306,SHP647,SHP647-306 Induction #2,III,Completed,GI,"1,032",34,0,0,0,0,7,3.29%,420,8,0,PPD,0,,,2017-12-21,,2018-06-11,2018-07-17,,2020-04-16,,2020-08-18,,,,,2020-11-24,,,,,98,5,5,,,,,36,,,,124
2089,SHPELA-701,Elaprase (idursulfase),PV Monitoring Study of Elaprase in Mexico,IV,Completed,RGH,25,5,0,0,0,0,0,20.00%,25,3,0,IQVIA,0,,2016-11-16,2016-11-16,,2018-01-19,,2017-11-30,2019-05-10,,2020-05-11,,,,,2020-08-28,,,,,109,5,5,,0,,,,,526,,367
2500,SPD489-348,Vyvanse (Lisdexamfetamine dimesylate),"A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed with Attention-deficit/Hyperactivity Disorder",III,Completed,NS,100,115,0,0,0,0,46,115.00%,54,1,0,Bracket,0,,2014-08-25,2014-10-21,,2015-08-21,2015-08-21,,2018-12-28,,2020-01-03,,,,,2020-01-30,,,,,27,5,5,,57,,,0,,,,371
2873,TAK-620-1019,maribavir (TAK-620),"A Phase 1, Open-label, Randomized,  Crossover, Bioavailability, Dose Proportionality, and Food Effect Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Subjects",I,Study Terminated,RGH,38,0,0,0,0,0,0,0,1,0,Shire,PPD,0,,2019-06-25,2019-07-24,,2019-10-18,2019-11-15,,,,2019-11-25,,,,,2020-03-03,,,,,99,5,5,,29,,,28,,,,
2874,TAK-620-1020,maribavir (TAK-620),"A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Subjects Compared with Matched, Healthy, Non-Hispanic, Caucasian Subjects and to Assess Dose-Proportionality of 3 Doses of Maribavir in the Japanese Subjects",I,Reported,RGH,24,24,0,0,0,0,0,100.00%,1,1,0,TBD,0,,2020-02-13,2020-04-08,,2020-08-07,2020-08-20,,2020-11-06,,2020-11-11,,,,,2021-12-15,,,,,399,5,5,,55,,,13,,,,5
2905,TAK-743-1003,Takhzyro (Lanadelumab),"TAK-743-1003 Safety, tolerability and PK trial using intravenous formulation in Healthy Volunteers",I,Reported,RGH,12,12,32,0,0,0,0,100.00%,1,0,0,Celerion,0,,,2020-07-22,,2020-08-10,2020-08-17,,2020-08-27,,2020-12-16,,,,,2021-01-26,,,,,41,5,5,,,,,7,,,,111
2917,TAK-888-2001,CoVIg-19,"An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19",III,Study Withdrawn,NonCore,500,0,0,0,0,0,0,0,30,0,0,0,0,,2020-04-15,2020-07-13,,2020-10-08,2020-10-08,,2021-02-10,,2021-03-10,,,,,2021-03-28,,,,,18,5,5,,89,,,0,,,,28
2919,TED-C13-003,Gattex (teduglutide),"A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year through 17 Years, with Short Bowel Syndrome who are Dependent on Parenteral Support",III,Completed,GI,42,42,0,0,0,0,0,100.00%,19,0,"(NPS) National Pharmaceutical Services, Inc",Psi,0,,2013-05-15,2013-07-03,,2013-11-14,2013-12-15,,2014-09-15,,2015-01-09,,,,,2015-02-05,,,,,27,5,5,,49,,,31,,,,116
2921,TED-C14-006,Gattex (teduglutide),"A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years With Short Bowel Syndrome who are Dependent on Parenteral Support",III,Completed,GI,34,59,71,0,12,0,0,173.53%,27,0,"(NPS) National Pharmaceutical Services, Inc",IQVIA,0,8/18/2017,2014-11-03,2015-03-12,,2016-06-02,2016-06-23,,2016-12-30,,2017-07-28,,,,,2017-10-20,,,,,84,5,5,-1019,129,,,21,,,,210
2951,DEN-001,TAK-003,Rapid Seroincidence and Syndromic Surveillance for Dengue and Norovirus in Latin America,0,Reported,NonCore,"2,000",0,0,0,0,0,0,0,4,0,0,TBD,0,,2014-04-23,2014-04-23,,2015-04-13,2015-04-13,,2016-03-31,,2016-12-31,,,,,2017-01-31,,,,,31,5,5,,0,,,0,,,,275
2952,DEN-002,TAK-003,Dengue as a cause of non-malarial febrile illness in Southwestern Uganda,0,Reported,NonCore,"1,200",0,0,0,0,0,0,0,3,0,0,TBD,0,,2017-02-28,2017-02-28,,2017-11-01,2017-11-01,,2018-07-18,,2018-07-18,,,,,2019-10-25,,,,,464,5,5,,0,,,0,,,,0
2956,DEN-101,0,"A Double-blind Randomized, Placebo-controlled, Phase I Dose Escalation Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers",I,Reported,NonCore,72,0,0,0,0,0,0,0,1,0,0,DMID-CROMS Pharmacovigilance Group,0,,2009-09-01,2009-11-01,,2010-06-07,2010-06-07,,2011-07-11,,2012-04-12,,,,,2012-12-04,,,,,236,5,5,,61,,,0,,,,276
2957,DEN-102,0,"A Phase I, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of DENVax Vaccine in Healthy Adults",I,Reported,NonCore,112,0,0,0,0,0,0,0,1,0,0,IQVIA,0,,2010-02-11,2010-02-11,,2010-10-11,2010-10-11,,2010-11-10,,2011-11-09,,,,,2013-05-01,,,,,539,5,5,,0,,,0,,,,364
2959,DEN-104,0,"A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicity of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18 – 45 Years",I,Reported,NonCore,144,0,0,0,0,0,0,0,3,0,0,TBD,0,,2011-09-25,2011-09-25,,2012-01-23,2012-02-01,,2013-08-26,,2014-01-06,,,,,2014-03-01,,,,,54,5,5,,0,,,9,,,,133
2965,DEN-203-2,TAK-003,"A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 – 45 Years",II,Reported,NonCore,360,0,0,0,0,0,0,0,8,0,0,Chiltern,0,,2011-06-16,2011-08-26,,2012-01-11,2012-01-11,,2013-04-01,,2016-04-01,,,,,2016-12-30,,,,,273,5,5,,71,,,0,,,,1096
2966,DEN-204,TAK-003,"A Phase II, double-blind, controlled trial to assess the Safety and Immunogenicity of different schedules of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in healthy subjects aged between 2 and <18 years and living in dengue endemic countries in Asia and Latin America",II,Reported,NonCore,"1,800","1,778",0,0,2,1800,0,98.78%,3,0,0,IQVIA,0,,2014-03-13,2014-03-13,,2014-12-05,2014-12-05,,2015-02-13,,2016-09-13,,,,2019-02-18,2016-12-30,,,,2019-08-01,108,5,5,,0,,,0,,,,578
2967,DEN-205,TAK-003,"A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine with two Different Serotype 2 Potencies in an Adult Population in Singapore",II,Reported,NonCore,400,351,0,0,0,0,29,87.75%,3,0,0,PPD,0,,2014-09-17,2015-01-25,,2015-06-03,2015-06-08,,2016-08-29,,2017-09-18,,,,,2018-01-11,,,,,115,5,5,,130,,,5,,,,385
2974,DEN-304,TAK-003,Lot-to-lot Consistency of 3 Lots of TDV in Non-Endemic Country(ies) for Dengue,III,Reported,NonCore,924,4,1007,0,85,0,111,0.43%,14,1,0,PPD,0,,2016-02-17,2017-07-18,,2018-02-12,2018-02-12,,2018-03-08,,2019-01-14,,,,,2019-05-22,,,,,128,5,5,,517,,,0,,,,312
2975,DEN-305,TAK-003,"A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever
YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects
Aged 18 to 60 years in Non-Endemic Country(ies)",III,Reported,NonCore,900,900,0,0,0,0,160,100.00%,11,0,0,PPD,0,,2016-02-17,2016-12-19,,2018-02-28,2018-02-28,,2018-03-27,,2019-05-13,,,,,2019-11-04,,,,,175,5,5,,306,,,0,,,,412
2977,DEN-307,TAK-003,End of shelf life,III,Recruitment Complete,NonCore,200,203,0,0,25,0,0,101.50%,0,0,0,IQVIA,0,,2018-02-15,2018-06-21,,2019-03-28,2019-03-28,,2019-05-31,,2020-03-13,,,,,2020-12-15,,,,,277,5,5,,126,,,0,,,,287
2983,DEN-313,TAK-003,"An open label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years",II,Recruitment Complete,NonCore,200,392,0,0,0,0,16,196.00%,2,2,0,PPD,0,,2016-07-01,2016-07-01,,2017-04-03,2017-04-03,,2017-06-02,,2020-09-29,,,,,2021-02-25,,,,,149,5,5,,0,,,0,,,,1215
2984,DEN-314,TAK-003,"A Phase III, observer-blinded, randomized trial to investigate the immunogenicity and safety of the co-administration of TDV and inactivated hepatitis A vaccine in healthy subjects aged 18 to 60 years from non-endemic areas",III,Reported,NonCore,900,899,0,0,0,0,121,99.89%,10,0,0,PPD,0,,2016-02-17,2016-08-31,,2018-05-16,2018-05-16,,2018-08-30,,2019-07-09,,,,,2019-10-02,,,,,85,5,5,,196,,,0,,,,313
2985,DEN-315,TAK-003,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate
the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent
Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic
Area(s) for Dengue",III,Reported,NonCore,400,400,0,0,0,0,9,100.00%,5,1,0,PPD,0,,2016-02-22,2016-10-28,,2017-12-14,2017-12-14,,2018-04-08,,2019-01-26,,,,,2019-05-08,,,,,102,5,5,,249,,,0,,,,293
2996,EPI-001,TAK-214,Active Surveillance for Medically-Attended Acute Gastroenteritis (MAAGE) and Norovirus Infection in a Managed Care Population,0,Reported,NonCore,"3,500",0,0,0,0,0,0,0,1,0,0,TBD,0,,2013-05-14,2013-05-14,,2014-03-15,2014-03-15,,2017-11-13,,2017-11-13,,,,,2018-01-31,,,,,79,5,5,,0,,,0,,,,0
2997,EPI-002,TAK-214,Community and hospital burden of norovirus disease in children,0,Reported,NonCore,"2,750",0,0,0,0,0,0,0,9,6,0,Assign Group,0,,2013-04-30,2013-09-26,,2014-11-24,2014-11-24,,2017-03-17,,2017-03-31,,,,,2018-08-31,,,,,518,5,5,,149,,,0,,,,14
2998,EPI-003A,TAK-214,"Norovirus acute gastroenteritis among international travelers from the United States, Switzerland and Germany (Norovirus Travel Study)",0,Completed,NonCore,"2,152",0,0,0,0,0,0,0,5,2,0,Assign Group,0,,2013-09-27,2013-09-27,,2015-03-06,2015-03-06,,2017-04-22,,2017-07-07,,,,,2019-12-13,,,,,889,5,5,,0,,,0,,,,76
3004,EPI-008,TAK-214,"Norovirus (NoV) Associated Gastroenteritis in a Pediatric Population from Cali, Colombia",0,Completed,NonCore,400,0,0,0,0,0,0,0,2,0,0,TBD,0,,2014-05-31,2014-05-31,,2015-03-12,2015-03-12,,2016-03-15,,2016-03-23,,,,,2016-06-30,,,,,99,5,5,,0,,,0,,,,8
3007,EPI-011,0,Osaka retrospective study - Community Dwelling,0,Reported,NonCore,"5,000",0,0,0,0,0,0,0,1,0,0,Mediscience Planning Inc.,0,,2015-06-30,2015-09-16,,2016-01-16,2016-01-16,,2017-03-31,,2017-03-31,,,,,2017-03-31,,,,,0,5,5,,78,,,0,,,,0
3008,EPI-012,TAK-214,Norovirus disease in Germany. A method- mix study to assess epidemiology and action processes,0,Reported,NonCore,"2,000",0,0,0,0,0,0,0,1,0,0,TBD,0,,2015-06-30,2015-06-30,,2016-11-01,2016-11-01,,2018-03-30,,2018-03-30,,,,,2018-04-30,,,,,31,5,5,,0,,,0,,,,0
3009,EPI-013,0,Burden of disease of norovirus gastroenteritis among hospitalized patients in Germany,0,Reported,NonCore,0,0,0,0,0,0,0,0,1,0,0,TBD,0,,2013-07-01,2013-07-01,,2014-02-15,2014-02-15,,2014-12-31,,2015-01-15,,,,,2015-01-31,,,,,16,5,5,,0,,,0,,,,15
3011,EPI-015,TAK-214,Early Bird Study (Immunologic and Genetic Markers of Protection to Norovirus),0,Reported,NonCore,100,0,0,0,0,0,0,0,1,0,0,TBD,0,,2013-03-01,2013-03-01,,2013-04-30,2013-04-30,,2017-05-09,,2017-05-09,,,,,2017-06-01,,,,,23,5,5,,0,,,0,,,,0
3013,EPI-017,TAK-214,Disease Burden of Norovirus in Children in Malawi,0,Reported,NonCore,"1,242",0,0,0,0,0,0,0,2,0,0,TBD,0,,2014-12-05,2015-07-23,,2015-10-31,2015-10-31,,2016-10-31,,2016-12-30,,,,,2018-04-30,,,,,486,5,5,,230,,,0,,,,60
3014,EPI-018,TAK-214,Seroprevalence of Norovirus antibodies in Chilean infants,0,Completed,NonCore,495,0,0,0,0,0,0,0,1,0,0,TBD,0,,2015-01-26,2015-01-26,,2015-05-31,2015-05-31,,2015-07-31,,2015-07-31,,,,,2016-06-30,,,,,335,5,5,,0,,,0,,,,0
3015,EPI-020,TAK-214,Burden of Norovirus disease among families from a semirural low-mid socioeconomic county (Colina) in a middle-high income country (Chile),0,Reported,NonCore,30,0,0,0,0,0,0,0,1,0,0,TBD,0,,2015-12-07,2015-12-07,,2016-04-11,2016-04-11,,2016-07-18,,2018-08-15,,,,,2018-08-30,,,,,15,5,5,,0,,,0,,,,758
3018,EPI-026,TAK-214,"The epidemiology of Norovirus in a pediatric population in a peri-urban area of Lima, Peru",0,Recruitment Complete,NonCore,800,0,0,0,0,0,0,0,2,1,0,IQVIA,0,,2018-02-26,2018-02-26,,2019-03-15,2019-03-15,,2019-10-31,,2020-04-08,,,,,2021-01-29,,,,,296,5,5,,0,,,0,,,,160
3031,IPV-102,TAK-195,"A Randomized, Observer-Blind, Controlled Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses of a Stand-alone Trivalent, Inactivated Poliomyelitis Vaccine from Sabin Strains in Healthy Infants, with a Safety and Tolerability Lead-in in Healthy Toddlers",I,Reported,NonCore,340,0,0,0,0,0,0,0,3,4,0,PRA Health Sciences,0,,2016-07-11,2016-11-23,,2017-06-07,2017-06-07,,2017-12-28,,2018-06-29,,,,,2018-12-14,,,,,168,5,5,,135,,,0,,,,183
3037,LV01-101,0,"Phase 1 Dose Escalation, Safety and Immunogenicity Study of Intranasal Norwalk VLP Vaccine with Adjuvant (MPL) and Excipients (Chitosan, Mannitol and Sucrose)",I,Completed,NonCore,28,0,0,0,0,0,0,0,1,0,0,"DP Clinical, Inc.",0,,2007-03-06,2007-03-06,,2007-04-09,2007-04-23,,2008-05-15,,2008-10-07,,,,,2009-10-12,,,,,370,5,5,,0,,,14,,,,145
3041,LV03-105,0,"Phase I - II, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety, Immunogenicity and Efficacy trial in Healthy Adults of Norovirus IM Bivalent VLP Vaccine in Experimental Human Norovirus GII.4 Disease",I,Completed,NonCore,132,0,0,0,0,0,0,0,5,0,0,"DP Clinical, Inc.",0,,2012-01-26,2012-01-26,,2012-02-17,2012-02-19,,2012-02-23,,2012-02-24,,,,,2012-03-02,,,,,7,5,5,,0,,,2,,,,1
3042,NOR-107,TAK-214,"Phase II, Dosage and Adjuvant Justification, Safety and Immunogenicity trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Adults",II,Reported,NonCore,420,0,0,0,0,0,0,0,2,0,0,IQVIA,0,,2013-10-10,2013-10-10,,2014-03-28,2014-03-28,,2014-05-22,,2015-06-19,,,,,2015-08-17,,,,,59,5,5,,0,,,0,,,,393
3044,NOR-201,TAK-214,"Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Adults",II,Reported,NonCore,450,0,0,0,0,0,0,0,10,0,0,IQVIA,0,,2013-12-13,2014-01-28,,2014-05-15,2014-05-15,,2014-07-02,,2016-01-14,,,,,2016-02-01,,,,,18,5,5,,46,,,0,,,,561
3045,NOR-202,TAK-214,"Phase II, Dose Finding, Age Step Down, Safety and Immunogenicity trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine in Children, Toddlers and Infants",II,Completed,NonCore,840,840,0,0,59,840,0,100.00%,12,0,0,IQVIA,0,,2013-12-03,2014-03-10,,2015-06-23,2015-06-23,,2017-07-25,,2018-06-20,,,,,2018-08-30,,,,,71,5,5,,97,,,0,,,,330
3046,NOR-204,TAK-214,"Phase II, Dosage and Adjuvant Confirmation, Age Step down, Safety and Immunogenicity trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Older Adults",II,Completed,NonCore,325,320,0,0,0,0,11,98.46%,10,0,0,PPD,0,,2014-06-26,2014-07-29,,2016-02-01,2016-02-01,,2016-09-02,,2017-09-29,,,,,2018-02-05,,,,,129,5,5,,33,,,0,,,,392
3050,NOR-210,TAK-214,"Phase II, Open label, Safety and Immunogenicity Study of Bivalent Norovirus Vaccine to generate High Titer Positive Control Serum",II,Completed,NonCore,50,50,0,0,0,0,2,100.00%,1,0,0,PPD,0,,2014-12-17,2015-01-19,,2015-02-26,2015-02-26,,2015-02-27,,2015-09-11,,,,,2015-10-29,,,,,48,5,5,,33,,,0,,,,196
3051,NOR-211,TAK-214,"Phase IIb, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years",II,Completed,NonCore,"4,176","4,758",0,0,751,0,0,113.94%,1,0,0,IQVIA,0,,2015-06-24,2015-07-27,,2016-06-14,2016-06-14,,2018-04-26,,2018-06-16,,,,,2018-08-08,,,,,53,5,5,,33,,,0,,,,51
3078,ZIK-101,TAK-426,"Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Adults",I,Recruiting,NonCore,240,271,894,0,623,271,20,112.92%,9,8,0,PRA Health Sciences,0,,2016-12-19,2017-01-29,,2017-11-13,2017-11-27,,2018-10-26,,2018-12-28,2019-11-21,,,2020-11-24,2019-05-28,2020-03-11,,,2021-06-14,151,5,5,,41,,,14,,,,63
